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survival of capsule-deficient, exopolysaccharide- deficient K. kingae to wild-type levels, demonstrating that
capsule and exopolysaccharide promote resistance to the classical complement pathway. Consistent with these
results, the capsule and exopolysaccharide enhanced K. kingae pathogenicity in juvenile rats with an intact
complement system. Loss of the capsule and the exopolysaccharide resulted in avirulence, however not in rats
lacking complement. Experiments using primary human neutrophils and a series of isogenic K. kingae
mutants demonstrated the critical role of the capsule and the conditional role of the exopolysaccharide in
preventing the neutrophil oxidative burst response and neutrophil- mediated killing of K. kingae. In the
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production. The loss of capsule promoted neutrophil binding of K. kingae but had no effect on neutrophil
phagocytosis and bacterial internalization of K. kingae. In contrast, the exopolysaccharide efficiently blocked
neutrophil phagocytosis of K. kingae and resisted the bactericidal effects of antimicrobial peptides. This works
establishes that the K. kingae surface polysaccharides are multi-functional and play a critical role in K. kingae
pathogenicity, facilitating evasion of host immunity. Our studies suggest that the K. kingae capsule and
exopolysaccharide have potential as targets for vaccine development.
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ABSTRACT
SURFACE POLYSACCHARIDES PROMOTE INNATE IMMUNE EVASION BY
THE PEDIATRIC PATHOGEN KINGELLA KINGAE
Vanessa Lynne Muñoz
Joseph W. St. Geme, III, M.D.

The gram-negative coccobacillus Kingella kingae is an emerging pediatric
pathogen and is increasingly recognized as a common etiological agent of osteoarticular
infections and bacteremia in young children. The pathogenesis of K. kingae disease
involves colonization of the posterior pharynx, invasion into the bloodstream, and
dissemination to distant sites of infection. Previous studies have revealed that K. kingae
produces a number of surface factors that may contribute to the pathogenic process,
including a polysaccharide capsule and an exopolysaccharide. The purpose of this work
was to determine the role of the K. kingae polysaccharide capsule and exopolysaccharide
in promoting resistance to complement-mediated and neutrophil-mediated killing.
We determined that both the K. kingae capsule and exopolysaccharide prevented
efficient binding of IgG, IgM, C4b, and C3b to the bacterial surface and inhibited
complement-mediated killing. Abrogation of the classical complement pathway using
EGTA-treated human serum restored survival of capsule-deficient, exopolysaccharidedeficient K. kingae to wild-type levels, demonstrating that capsule and exopolysaccharide
promote resistance to the classical complement pathway. Consistent with these results, the
vi

capsule and exopolysaccharide enhanced K. kingae pathogenicity in juvenile rats with an
intact complement system. Loss of the capsule and the exopolysaccharide resulted in
avirulence, however not in rats lacking complement.
Experiments using primary human neutrophils and a series of isogenic K. kingae
mutants demonstrated the critical role of the capsule and the conditional role of the
exopolysaccharide in preventing the neutrophil oxidative burst response and neutrophilmediated killing of K. kingae. In the absence of capsule, the exopolysaccharide prevented
K. kingae opsonization and subsequently, reduced ROS production. The loss of capsule
promoted neutrophil binding of K. kingae but had no effect on neutrophil phagocytosis and
bacterial internalization of K. kingae. In contrast, the exopolysaccharide efficiently blocked
neutrophil phagocytosis of K. kingae and resisted the bactericidal effects of antimicrobial
peptides.
This works establishes that the K. kingae surface polysaccharides are multifunctional and play a critical role in K. kingae pathogenicity, facilitating evasion of host
immunity. Our studies suggest that the K. kingae capsule and exopolysaccharide have
potential as targets for vaccine development.
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1. Introduction
1.1 Kingella kingae history and pathogenicity
Kingella kingae was first isolated in the 1960’s by Elizabeth O. King at the Centers
for Disease Control in Atlanta, GA (Bovre, 1976; Henriksen & Bovre, 1968). The species
belongs to the Neisseriaceae family under the Kingella genus, along with K. denitrificans,
K. oralis, K. negevensis, and K. potus (Bovre, 1976; C. Chen, 1996; El Houmami et al.,
2017; Lawson et al., 2005; Maccato, McLean, Riddle, & Faro, 1991). K. kingae is a betahemolytic gram-negative coccobacillus and is most often isolated from human respiratory
secretions and from systemic sites in patients with bacteremia, endocarditis, osteomyelitis,
or septic arthritis (Henriksen & Bovre, 1968). The organism can be recovered from the
human oropharynx as a part of the oral commensal flora and primarily colonizes children
between the ages of 6 and 36 months (Amit, Dagan, & Yagupsky, 2013; Yagupsky, Porat,
& Pinco, 2009).
As an emerging pediatric pathogen, K. kingae is increasingly recognized as the
primary etiology of osteoarticular infections, a common etiology of bacteremia, and an
occasional etiology of endocarditis in young children (Chometon et al., 2007b; Yagupsky,
2014; Yagupsky, Erlich, Ariela, Trefler, & Porat, 2006; Yagupsky, Porsch, & St Geme III,
2011). Invasive K. kingae disease is frequently associated with a concurrent viral
respiratory infection in patients (J Amir & Yagupsky, 1998; Kiang et al., 2005; Seña, Seed,
Nicholson, Joyce, & Cunningham, 2010; Yagupsky, 2004; Yagupsky & Dagan, 1994).
Typically, patients under four years of age with invasive K. kingae disease are healthy,
whereas older patients often have underlying health issues, including immunosuppression
1

or cardiac valve pathology (Dubnov-Raz et al., 2008, 2010; Yagupsky, 2004). The rate of
K. kingae colonization in the oropharynx peaks between 12- to 24-months of age and
steadily decreases as the child ages (Yagupsky, Dagan, Prajgrod, & Merires, 1995;
Yagupsky, Peled, & Katz, 2002). This age-related pattern of colonization correlates with
the development of the adaptive immune response against K. kingae (Yagupsky et al.,
1995, 2002). Asymptomatic colonization of the oropharynx is considered an immunizing
event due to the increase in K. kingae cross-reactive antibody levels in older children and
adults regardless of whether the child presents with invasive K. kingae disease (Slonim,
Steiner, & Yagupsky, 2003; Yagupsky et al., 2011).
Oropharyngeal colonization by K. kingae presumably begins with adherence to
respiratory epithelial cells. In vitro studies demonstrate that adherence to human epithelial
cells is mediated by two identified adhesins in K. kingae, type IV pili and the
autotransporter protein Knh (Kehl-Fie et al., 2010; Kehl-Fie, Miller, & St. Geme, 2008;
Kehl-Fie, Porsch, Miller, & St. Geme III, 2009; Porsch, Kehl-Fie, & St. Geme III, 2012).
K. kingae interaction with epithelial cells is initiated by initial low-affinity adherence
through type IV pili engagement with host receptors (Kern, Porsch, & St. Geme, 2017;
Porsch et al., 2012). Subsequently, pili binding and retraction results in polysaccharide
capsule displacement and Knh-mediated high-affinity adherence (Kern et al., 2017; Porsch
et al., 2012).
K. kingae type IV pili are comprised of the major pilin subunit, PilA1, and two
minor pilus-associated proteins, PilC1 and PilC2 (Kehl-Fie et al., 2008; Porsch et al.,
2013). The PilA1 protein in K. kingae is homologous to other major type IV pilins found
2

in pathogens such as Neisseria meningitidis and Neisseria gonorrhoeae. Deletion of pilA1
in K. kingae renders the bacterium nonpiliated and unable to adhere to epithelial cells or
undergo twitching motility (pilus-dependent extension and retraction) in vitro (Kehl-Fie et
al., 2008; Porsch et al., 2012). PilA1 expression is regulated by the PilS and PilR twocomponent system and sigma factor s54; elimination of PilR and s54 results in a drastic loss
of piliation whereas elimination of PilS only slightly affects piliation (Kehl-Fie et al.,
2009). Further examination of the pilin-encoding region of K. kingae determined that pilA1
is transcribed upstream of two pilin-like genes, pilA2 and fimB (Kehl-Fie et al., 2008).
However, transcriptional analysis and transmission electron micrographs demonstrated
that in-frame deletions of pilA2 and fimB did not alter K. kingae piliation or adherence (the
function of these two pilin-like genes remains unknown) (Kehl-Fie et al., 2008). The two
minor pilus-associated proteins, PilC1 and PilC2, are encoded elsewhere in the genome
and are homologous to the N. meningitidis and N. gonorrhoeae PilC proteins and the
Pseudomonas aeruginosa PilY protein (Kehl-Fie et al., 2008; Porsch et al., 2013).
Expression of either PilC1 or PilC2 promotes piliation, and deletion of both pilC1 and
pilC2 results in a decrease of surface pili and loss of the adherence and twitching motility
phenotype (Kehl-Fie et al., 2008; Porsch et al., 2013). Unlike the situation with mutations
in PilR and s54, levels of PilA1 are not affected in the pilC1 and pilC2 double mutant,
suggesting that the PilC proteins are either required or regulate pili assembly (Kehl-Fie et
al., 2009; Porsch et al., 2013). The variability of K. kingae piliation across strains can be
associated with the clinical site of isolation with most pharyngeal and bacteremia isolates,
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expressing pili, while bone, joint, or endocarditis isolates generally being nonpiliated
(Kehl-Fie et al., 2010, 2008).
Knh (Kingella NhhA homolog) is a predicted 540 kDa trimeric autotransporter
adhesin that forms short fibers on the K. kingae bacterial surface (Kern et al., 2017; Porsch
et al., 2012). Elimination of Knh reduces, but does not completely abrogate K. kingae
adherence to human epithelial cells (Porsch et al., 2012). Knh-mediated adherence is
dependent on the retraction of type IV pili to displace the polysaccharide capsule and
unmask Knh (Kern et al., 2017; Porsch et al., 2012). The inhibition of Knh-mediated
adherence by capsule is suspected to be caused by the stark differences in Knh length and
capsule depth, ~110 nm and ~700 nm, respectively (Kern et al., 2017). Similar to the
HMW1/HMW2 adhesins of Haemophilus influenzae, Knh is N-glycosylated by an
HMWC-like glycosyltransferase enzyme (Rempe et al., 2015). In the absence of
glycosylation, Knh levels in the outer membrane are reduced and adherence to epithelial
cells and autoaggregation is lost (Rempe et al., 2015). Annotation and analysis of the Knh
amino acid sequence unveiled the presence of two predicted domains associated with
adhesive activity, an ISneck2 domain located near the membrane anchor and multiple
YadA-like head domains located near the N-terminus (Porsch et al., 2012). Regulation of
Knh expression and the mechanism of presentation on the bacterial surface remains largely
uncharacterized. However, preliminary data suggest that two genes immediately
downstream of knh designated knhB and knhC may play a role in the presentation of Knh
on the bacterial surface, as elimination of KnhB and KnhC slightly alters Knh-mediated
adherence and autoaggregation of K. kingae (unpublished data).
4

Biofilm formation facilitates bacterial adherence and establishment of colonization
in microbial communities. K. kingae cell-free extracts from biofilms exhibit broadspectrum anti-biofilm activity (Bendaoud et al., 2011). Examination of the K. kingae
extracts determined the presence of two surface polysaccharides, the polysaccharide
capsule and an exopolysaccharide (Bendaoud et al., 2011). The exopolysaccharide locus
contains five genes (pamA, pamB, pamC, pamD, and pamE) and expression of pamABCDE
or pamABC produces a galactan homopolymer (Bendaoud et al., 2011). Two unique
exopolysaccharide structures have been identified so far (Bendaoud et al., 2011; Starr et
al., 2013). Purified exopolysaccharide material, which is structually distinct from the
polysaccharide capsule, prevents the biofilm formation of numerous microbes through
surface

physiochemical

modifications

(Bendaoud

et

al.,

2011).

Release

of

exopolysaccharide by K. kingae is speculated to enhance colonization by inhibiting biofilm
formation of other commensal organisms and establishing its niche in the oropharynx. In
an infant rat infection model, elimination of the exopolysaccharide attenuated K. kingaeinduced morbidity and mortality, suggesting that the exopolysaccharide plays a significant
role in K. kingae virulence (Muñoz, Porsch, & St. Geme, 2018).
Following asymptomatic colonization in the respiratory tract, K. kingae must
breach the respiratory epithelium, enter the bloodstream, and spread to distant sites for
disease progression (Amit et al., 2013; Bidet et al., 2013; Yagupsky et al., 2006, 2009). It
is hypothesized that bloodstream invasion of K. kingae is facilitated by disruption of the
respiratory epithelium due to viral co-infection and secretion of the K. kingae RtxA
cytotoxin (Amit et al., 2012; Kehl-Fie & St. Geme III, 2007; Yagupsky et al., 2011). K.
5

kingae displays a wide range of cellular toxicity, and generation of a transposon mutant
library identified the rtx locus as essential for cytotoxicity against epithelial, synovial, and
macrophage-like cells in vitro (Kehl-Fie & St. Geme III, 2007). Furthermore, an RtxAdeficient K. kingae mutant was associated with higher survival percentages and increased
white blood cell counts when compared to wild type K. kingae in an infant rat infection
model (Chang, Nudell, Lau, Zakharian, & Balashova, 2014). The rtx locus contains five
genes (rtxB, rtxD, rtxA, rtxC, and tolC) necessary for the production and secretion of the
RtxA toxin (Kehl-Fie & St. Geme III, 2007). Genetic analysis of the rtx locus and flanking
regions suggests that the locus was acquired by K. kingae via horizontal transfer given the
high homology to Moraxella bovis insertional elements and the M. bovis rtx locus (KehlFie & St. Geme III, 2007). RtxA is secreted by K. kingae through the type I secretion
system (RtxB, RtxD, and TolC) and is present in cytotoxic and hemolytic outer membrane
vesicles (Kehl-Fie & St. Geme III, 2007; Maldonado, Wei, Kachlany, Kazi, & Balashova,
2011). RtxA induces cytotoxity through pore formation across planar lipid membranes;
cation-selectivity of the RtxA channel induces a cation flux and programmed cell death
(Bárcena-Uribarri, Benz, Winterhalter, Zakharian, & Balashova, 2015). Post-translational
acylation of RtxA lysine residues and cholesterol binding are critical for the cytotoxic
activity of RtxA (Osickova et al., 2018).
Bacterial encapsulation provides a variety of benefits to microbes by allowing the
organism to tolerate environmental stressors and evade host immunity during infection. K.
kingae produces a polysaccharide capsule that enhances virulence in the infant rat infection
model (Muñoz et al., 2018; Starr, Porsch, Seed, & St. Geme III, 2016). The polysaccharide
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capsule in conjunction with the exopolysaccharide can protect K. kingae from complementmediated lysis by preventing opsonin deposition and complement activation (Muñoz et al.,
2018). In K. kingae, four distinct polysaccharide capsules (types a, b, c, and d) have been
identified, with capsule types a and b accounting for greater than 95% of invasive disease
isolates (Porsch, Starr, Yagupsky, & St. Geme III, 2017; Starr, Porsch, Seed, Heiss, et al.,
2016). Genetic analysis of K. kingae genomes revealed that clinical isolates contain one of
four capsule-specific biosynthesis loci (csa, csb, csc, and csd), as well as a capsule export
operon (ctrABCD) and capsule assembly genes (lipA and lipB) (Starr, Porsch, Seed, Heiss,
et al., 2016; Starr, Porsch, Seed, & St. Geme III, 2016). Unlike the exopolysaccharide, the
four K. kingae capsule types stain with cationic ferritin, which is consistent with anionic
properties (Starr et al., 2013).
As outlined, K. kingae expresses a number of surface or secreted factors that have
been characterized as potential virulence factors necessary for K. kingae colonization and
dissemination during pathogenesis (Table 1, Fig. 1).

Factor
Capsule

Exopolysaccharide

Table 1: K. kingae surface or secreted factors
Functions and comments
- Protects against complement-mediated lysis, neutrophil
activation and association, and antimicrobial peptides
- Promotes virulence in vivo
-

Protects against complement-mediated lysis, neutrophil
phagocytosis, and antimicrobial peptides
Inhibits biofilm production of other microbes
Promotes virulence in vivo

Knh

-

Promotes adherence to epithelial cells

OMVs

-

Wide-spectrum cytoxicity
Contains RtxA, PilC2, and polysaccharide capsule
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RtxA

-

Type IV pili

-

Wide-spectrum cytoxicity
Promotes virulence in vivo

Promote adherence to epithelial cells, twitching motility,
and natural competence
- Contain PilC1 and PilC2
*OMVs, outer membrane vesicles

Figure 1: Diagram of K. kingae virulence factors.
K. kingae surface or secreted factors that are hypothesized to influence colonization
(bottom) or dissemination (top).
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1.2 Bacterial surface polysaccharides
1.2.1 Lipopolysaccharides
Gram-negative bacterial cell walls are multilayered barriers comprised of an inner
membrane, an outer membrane, and a thin peptidoglycan layer within the periplasmic space
between the two membranes. The bacterial outer membrane consists of phospholipids,
lipoproteins, surface proteins, and lipopolysaccharides (LPS). For gram-negative bacteria,
the outer membrane is an asymmetric bilayer, with LPS localizing to the outer leaflet
(Funahara & Nikaido, 1980; Kamio & Nikaido, 1976; Mühlradt & Golecki, 1975). The
LPS (also known as endotoxin) composition is characterized by three separate structural
components: lipid A, a core oligosaccharide, and an O-antigen repeating polysaccharide.
Lipid A has a N-acetylglucosamine backbone that is highly acylated. As a
phospholipid, lipid A anchors LPS to the hydrophobic outer membrane (Raetz, 1990; Raetz
& Whitfield, 2002; Rietschel et al., 1994). For the majority of gram-negative bacteria, lipid
A is required for growth, stability, and maintenance of the outer membrane barrier
(Galloway & Raetz, 1990; Onishi et al., 1996; M. Vaara, 1993). Lipid A is highly
conserved across bacterial species, and due to this conservation, fragmented or released
LPS can be detected at the picomolar level by the host immune system (Aderem &
Ulevitch, 2000; Medzhitov & Janeway, 2000). Innate immune cells, such as macrophages
and neutrophils, along with endothelial cells, express Toll-like receptor 4 (TLR4), which
binds lipid A moieties to trigger downstream immune cell activation and the release of
inflammatory mediators (Beutler & Cerami, 1988; Dinarello, 1991; Drake, Cheng, Chang,
& Taylor, 1993; Hoshino et al., 1999; Poltorak et al., 1998). While productive immune
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responses to LPS promote bacterial clearance, lipid A is considered responsible for the
toxicity of LPS, and overproduction of inflammatory mediators systemically can lead to
cellular damage and septic shock in the host (Parrillo, 1993; van Deuren, Brandtzaeg, &
van der Meer, 2000).
The core oligosaccharide in LPS can be segmented further into the inner core,
which is proximal to lipid A, and the outer core, which attaches the O antigen (Raetz &
Whitfield, 2002). The inner core of most LPS structures contains keto-deoxyoctulosonate
(Kdo) residues and can be modified with phosphates, phosphorylcholine, or
phosphorylethanolamine residues (Brade, Opal, Vogel, & Morrison, 1999; Raetz &
Whitfield, 2002). Diversity in modifications of the inner core provides heterogeneity of the
LPS inner core; however, the outer core displays increased structural diversity (Raetz &
Whitfield, 2002). The structural diversity of the LPS outer core is thought to be shaped by
environmental pressures. Despite variation, the structural composition of the core
oligosaccharide remains largely conserved among species within the same genus or family
(Raetz & Whitfield, 2002). Conservation of the LPS core suggests that the structure is
essential for bacterial membrane stability and integrity (Raetz & Whitfield, 2002).
Unlike lipid A and the core oligosaccharide, O-antigen polymers are vastly diverse
even within a single species. Differences in the O-antigen structural composition can be
due to changes in the glycosidic linkages, monomers, branching patterns, and inclusion of
noncarbohydrate components (Brade et al., 1999; Knirel’ & Kochetkov, 1994).
Heterogeneity is also observed in the O-antigen chain length, and LPS visualization on a
gel exhibits a laddering effect due to variations in extension and addition of O units (Raetz
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& Whitfield, 2002). The O-antigen polysaccharide provides protection against a host of
immune responses, and recognition of the O-antigen by immune components depends on
the structure, abundance, and length of the O-antigen (Burns & Hull, 1998; Joiner, 1988;
Weiss, Hutzler, & Kao, 1986). Moreover, a loss or shortening of the O-antigen can hinder
bacterial colonization and/or virulence (Nesper et al., 2001; R. C. Sandlin et al., 1995;
Robin C. Sandlin, Goldberg, & Maurelli, 1996; Van den Bosch, Manning, & Morona,
1997). The extent of protection and virulence provided by the O-antigen varies drastically
across strains due to the wide range of structural diversity.
Many mucosal pathogens such as H. influenzae and N. meningitidis express solely
the lipid A moiety and the core oligosaccharide, producing a lipooligosaccharide (LOS)
that lacks the O-antigen (Raetz & Whitfield, 2002). LOS is also found in the outer leaflet
of the outer membrane and has been demonstrated to mediate adherence and invasion of
host cells in some species (Song, Ma, Chen, & Stein, 2000; van Vliet et al., 2009; Wetzler,
Barry, Blake, & Gotschlich, 1992). Despite lacking the hypervariable O-antigen polymer,
mucosal pathogens can adapt to immune and environmental pressures through phase
variation prompting the expression of various forms of the LOS structure (Brade et al.,
1999; Giardina, Weiss, Gibson, & Apicella, 2001; Hood et al., 1999). The LOS core is
comprised of an inner core that is often decorated with either mono- or oligosaccharide
branches (considered the outer core), which are the determinants of antigenicity (Brade et
al., 1999; Giardina et al., 2001; Hood et al., 1999). Sialylation and host-antigen mimicry
of LOS structures promotes colonization and immune evasion by mucosal pathogens (R.
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E. Mandrell et al., 1991; Robert E. Mandrell & Apicella, 1993; Moran, Prendergast, &
Appelmelk, 1996).

1.2.2 Polysaccharide capsules
Capsular polysaccharides are lipidated, surface-anchored carbohydrate chains that
contain multiple repeating saccharide units. Similar to the O-antigen present in LPS,
capsules can consist of variations in sugar polymers, cyclic and isomer forms, and
glycosidic linkages to generate unique antigenic epitopes within and across bacterial
species. Polysaccharide capsules are generally considered anionic and highly hydrated,
generating a mucoid-like phenotype (Gotschlich, Fraser, Nishimura, Robbins, & Liu,
1981). While the capsule biosynthesis genes necessary for polysaccharide production tend
to be genetically diverse, the export and assembly machinery remains highly conserved
across encapsulated gram-negative bacteria (Whitfield, 2006; Whitfield & Roberts, 1999).
For N. meningitidis, H. influenzae, and E. coli, a set of six conserved genes allow for
polysaccharide capsule presentation (M Frosch, Edwards, Bousset, Krausse, &
Weisgerber, 1991). Four of six conserved gene products form an ATP-binding cassette
transporter system that facilitates proper export through ATP-hydrolysis and insertion of
the polysaccharide capsule into the outer membrane (M. Frosch, Müller, Bousset, &
Müller, 1992; Larue, Ford, Willis, & Whitfield, 2011; Pazzani et al., 1993). As the result
of the highly selective pressure exerted by the immune system, polysaccharide diversity
within a given species can be relatively high (e.g., E. coli, ~80 serotypes; N. meningitidis,
13 serotypes; H. influenzae, 6 serotypes) (Cartwright, 1995; Moxon & Vaughn, 1981;
Orskov, Orskov, Jann, & Jann, 1977; Whitfield, 2006). Interestingly, the pathogenicity of
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a given pathogen can be dependent on the capsular type expressed, as certain capsules
highly correlate with invasive disease, most notably the H. influenzae serotype b capsule
(Cartwright, 1995; Moxon & Kroll, 1988; Moxon & Vaughn, 1981).
Polysaccharide capsules are critical virulence factors for many microorganisms and
have been widely shown to protect bacteria against mucosal and intravascular
inflammatory immune responses (Campos et al., 2004; Lambris, Ricklin, & Geisbrecht,
2008; Moxon & Vaughn, 1981; Nelson et al., 2007; Zwahlen, Kroll, Rubin, & Moxon,
1989). The presence of capsule masks bacterial surface antigens recognized by antibodies
or complement fragments. By preventing detection of these antigenic epitopes, capsules
impede antibody and complement opsonization and thus efficiently protect the bacterium
from complement-mediated lysis and neutrophil phagocytosis. Neutrophils have
negatively charged surfaces, and therefore, expression of polysaccharide capsules
increases electrostatic repulsion and reduces or prevents phagocytosis by enhancing the
anionic properties of the bacterial surface (Jarvis & Vedros, 1987). Beyond physical
hinderances, polysaccharide capsules can incorporate sialic acids into the repeating unit
mimicking host moieties and effectively averting detection by the host immune system
(Matthias Frosch & Maiden, 2006). Furthermore, sialic acid incorporation into the
polysaccharide structure can recruit the complement regulatory protein, factor H (Meri &
Pangburn, 1990; Schneider et al., 2006). Factor H acts on the complement alternative
pathway by binding factor I, which cleaves complement fragment C3b into an inactive
form, iC3b, and promotes decay of the C3 convertase, inhibiting the feedback loop of the
alternative pathway.
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Immunogenic studies performed in mice revealed a T-cell independent response to
polysaccharide capsules during immunization (Barrett, 1985; A. Coutinho, Möller,
Anderson, & Bullock, 1973; Antonio Coutinho & Möller, 1973). Due to the nature of the
response, a lack of IgM to IgG class-switching during initial infection leads to inefficient
antibody production and B-cell memory response upon re-challenge. To overcome the
hallmark characteristics of a T-cell independent response, chemical conjugation of
polysaccharide capsules to carrier proteins redirects the capsule to a T-cell dependent
response and boosts capsule-specific memory B-cells, providing lasting immunity (Kelly
et al., 2006; MacLennan et al., 2001). The polysaccharide capsules of S. pneumoniae, H.
influenzae, and N. meningitidis have been extensively studied due to their importance as
virulence factors and their effective use as polysaccharide-conjugate vaccines (Goldblatt,
2000).

1.2.3 Exopolysaccharides
Exopolysaccharides are high molecular weight homo- or hetero-sugar polymers
synthesized by bacteria and secreted into the extracellular milieu. Distinct characterization
and clustering of exopolysaccharides can be difficult due to the heterogeneity across
species, but polymers most commonly incorporate glucans, fructans, polygalactans,
glucose, galactose, and rhamnose into the exopolysaccharide repeating unit (Gherardini &
Helmer-Citterich, 2008; Ruas-Madiedo, Hugenholtz, & Zoon, 2002). The functionality of
a given exopolysaccharide depends on the polymer structure, composition, and abundance.
Bacterial exopolysaccharides have been studied primarily in relation to biofilms,
specifically attributing to adherence, bacterial cell aggregation, water retention, nutrient
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scavenging, and various other processes during biofilm formation and dispersal (Cerning,
1991; De Vuyst & Degeest, 1999; Flemming, Neu, & Wozniak, 2007; Watnick & Kolter,
2000). As a major contributor to the formation of biofilms, exopolysaccharides can provide
scaffolding for the biofilm matrix and are necessary for adherence and cohesiveness during
initial attachment to surfaces and microcolony establishment (Flemming & Wingender,
2010;

Rehm,

2010).

Furthermore,

differences

in

hydrophobicity

of

diverse

exopolysaccharides can alter the biofilm architecture, stability, and storage of nutrients and
enzymes (Nwodo, Green, & Okoh, 2012). While exopolysaccharide production is speciesspecific, environmental factors such as temperature, pH, nutrient availability, and growth
conditions can influence exopolysaccharide yield and biofilm formation (Looijesteijn, van
Casteren, Tuinier, Doeswijk-Voragen, & Hugenholtz, 2000).
Exopolysaccharides produced by pathogens such as Pseudomonas aeruginosa,
extraintestinal pathogenic E. coli, and Bordetella pertussis promote pathogenesis beyond
biofilm formation through evasion of cellular and humoral innate immune components
(Ganguly, Johnson, Kock, Parks, & Deora, 2014; Jones & Wozniak, 2017; Miajlovic,
Cooke, Moran, Rogers, & Smith, 2014; Mishra et al., 2012). Despite lacking a membraneanchor, these exopolysaccharides exhibit similar properties to bacterial polysaccharide
capsules by providing protection against neutrophil and complement activation and
decreasing sensitivity to antimicrobial peptides and reactive oxygen species. Moreover,
exopolysaccharides have also been demonstrated to interact with immune cells and can
stimulate or dampen inflammatory responses during infection (Jones & Wozniak, 2017;
Totté et al., 2015).
15

Various bacterial exopolysaccharides exhibit advantageous properties such as high
viscosity, gelling capacity, tensile strength, stability, and low solubility (Nwodo et al.,
2012). Synthetically polymerized exopolysaccharides, which can be valuable biomaterials,
are frequently used for commercial and medical purposes. Common exopolysaccharides
used in the food, petroleum, and pharmaceutical industries are alginate, cellulose, dextran,
and xanthan (Nwodo et al., 2012). Several distinct forms of alginate are effective in the
treatment of thromboembolic disorders due to the therapeutic characteristics, including
anti-angiogenesis and anticoagulation (Alban, 2002). Xanthan gum has been utilized for a
broad spectrum of diverse applications not limited to oil drilling, pesticides, and aqueous
systems (Nwodo et al., 2012; Rosalam & England, 2006).

1.2.4 K. kingae surface polysaccharides
Analysis of an Israeli collection containing over 400 K. kingae clinical isolates from
invasive disease and asymptomatic carriers revealed that greater than 99% of isolates
screened were encapsulated (Starr, Porsch, Seed, Heiss, et al., 2016). PCR amplification
revealed four distinct amplicons in the capsule synthesis locus (Starr, Porsch, Seed, Heiss,
et al., 2016). Nucleotide sequencing revealed four unique loci, with one locus containing
a single gene and three of the loci containing three genes (csaA, csbABC, cscABC, and
csdABC) (Starr, Porsch, Seed, Heiss, et al., 2016). The capsule loci nomenclature was
designated based on the type of capsule produced (e.g., csaA, capsule synthesis
type a gene A) (Starr, Porsch, Seed, Heiss, et al., 2016; Starr, Porsch, Seed, & St. Geme
III, 2016). Structural analyses were performed for purified capsule material from 12 K.
kingae strains expressing one of the four capsule loci. The analysis revealed the distinct
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polymer composition and linkages of the four capsule types (type a, [3)-β-GalpNAc(1→5)-β-Kdop-(2→]; type b, [6)-α-D-GlcpNAc-(1→5)-β-(8-OAc)Kdop-(2→]; type c,
[3)-β-D-Ribf-(1→2)-β-D-Ribf-(1→2)-β-D-Ribf-(1→4)-β-Kdop-(2→]; and type d, [P(O→3)[β-D-Galp-(1→4)]-β-D-GlcpNAc-(1→3)-α-D-GlcpNAc-1-])

(Fig.

2)

(Starr,

Porsch, Seed, Heiss, et al., 2016). Within the Israeli K. kingae collection, 239 strains were
isolated from healthy carriers and 178 strains were isolated from K. kingae infections
(Starr, Porsch, Seed, Heiss, et al., 2016). Capsule typing revealed that greater than 95% of
invasive isolates expressed either a type a or type b capsule; in comparison, 68% of carrier
isolates expressed either a type a or type b capsule (Starr, Porsch, Seed, Heiss, et al., 2016).
Types c and d represented 12% and 20% of carrier isolates, respectively; these percentages
dropped to a combined 4% representation in the invasive isolates (Starr, Porsch, Seed,
Heiss, et al., 2016). The distribution of capsule types in invasive versus carrier isolates was
further validated by applying a multiplex PCR approach to an international collection of
K. kingae clinical isolates (Porsch et al., 2017).
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Figure 2: Structure of the polysaccharide capsules and exopolysaccharide types
present in K. kingae clinical isolates.
The polysaccharide capsule repeating unit structures (top panel) and the
exopolysaccharide repeating unit structures (bottom panel). Top panel: capsule type
a (A, GalNAc-Kdo), capsule type b (B, GlcNAc-Kdo), capsule type c (C, ribose-Kdo),
and capsule type d (D, galacose-GlcNAc). Bottom panel: exopolysaccharide type 1 (1,
galactan monosaccharide) and exopolysaccharide type 2 (2, galactan disaccharide).
Adapted from (Starr et al., 2013) and (Starr, Porsch, Seed, Heiss, et al., 2016).
Studies performed with K. kingae strain KK01, which expresses a type a capsule,
demonstrated that capsule expression was necessary for full virulence in an infant rat
infection model (Muñoz et al., 2018; Starr, Porsch, Seed, & St. Geme III, 2016).
Furthermore, due to the depth of the polysaccharide capsule, surface antigens, including
the autotransporter adhesin, Knh, present on the bacterial surface are masked. Masking of
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these surface epitopes enhances survival of K. kingae in the presence of serum and
modulates K. kingae adherence to epithelial cells (Kern et al., 2017; Muñoz et al., 2018;
Porsch et al., 2012).
Gas chromatography and nuclear magnetic resonance determined the glycosyl
structure of surface polysaccharides from invasive K. kingae strains, KK01 and PYKK181
(Bendaoud et al., 2011; Starr et al., 2013). Analysis determined that in addition to the
polysaccharide capsule, strain KK01 produces a →5)-β-Galf-(1→ exopolysaccharide and
strain PYKK181 produces a →3)-β-Galf-(1→6)-β-Galf-(1→ exopolysaccharide (Fig. 2)
(Bendaoud et al., 2011; Starr et al., 2013). Both exopolysaccharides are linear galactan
homopolymer exopolysaccharides with distinct glycosyl linkages (Bendaoud et al., 2011;
Starr et al., 2013). The KK01 and PYKK181 exopolysaccharides were designated as type
1 and type 2, respectively (Fig. 2). As previously mentioned in Ch. 1.1, expression of the
type 2 exopolysaccharide from K. kingae or from an inducible plasmid in E. coli
demonstrated that the exopolysaccharide exerted potent anti-biofilm properties inhibiting
biofilm formation by gram-negative and gram-positive bacteria, as well as the fungal
pathogen, Candida albicans (Bendaoud et al., 2011). In vivo juvenile rat studies using
derivatives of strain KK01 demonstrated that the type 1 exopolysaccharide was necessary
for full K. kingae virulence (Muñoz et al., 2018).
So far, there are no current publications identifying LPS genes or loci present in the
K. kingae genome. Likewise, chemical or structural composition analyses of the K. kingae
LPS, or more likely LOS, in clinical isolates has not been performed. Current ongoing
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studies aim to address these critical gaps in knowledge in the attempt to broaden the
understanding of K. kingae surface polysaccharides and involvement in pathogenesis.

1.3 Innate immunity
The immune system functions to protect the host against a variety of disease states,
including invasion by microbial pathogens. Broadly, immunity can be divided into two
main branches: innate immunity and adaptive immunity. Innate immunity is considered a
non-specific, general response to foreign bodies, whereas adaptive immunity is considered
a specialized, targeted response to specific antigens. Children rely heavily on the protective
advantages of the innate immune system, as the adaptive immunity fully develops during
childhood (Janeway, Travers, Walport, & Shlomchik, 2001). While innate immunity is
composed of multiple cellular and humoral components, two key players are neutrophils
and the complement system.

1.3.1 Neutrophils
Neutrophils are the most abundant leukocyte (50-70%) present in human blood
(Döhrmann, Cole, & Nizet, 2016). Human neutrophils are characterized by their segmented
nucleus and the presence of multiple cytoplasmic vesicles (Borregaard, 2010). Generated
in the bone marrow, terminally-differentiated neutrophils circulate in the bloodstream and
are considered the first line of cellular defense during infection. Macrophages, mast cells,
and complement recruit neutrophils to the site of inflammation by releasing
chemoattractants (e.g., C5a, interleukin 8 (IL-8), and monocyte chemotactic factor),
promoting expression of endothelial-leukocyte adhesive molecules (e.g., P- and E-selectins
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and integrin CD11b/CD18) and increasing cell permeability (Kolaczkowska & Kubes,
2013; Phillipson & Kubes, 2011). Upon recruitment and extravasation, activated
neutrophils contain an arsenal of anti-microbial mechanisms to effectively combat
infection.
As phagocytic cells, neutrophils bind and engulf microbes through the expression
of surface receptors that recognize opsonins and foreign surfaces (Borregaard, 2010;
Phillipson & Kubes, 2011). After phagocytosis, phagocytic vacuoles fuse with lysosomes
to form mature phagolysosomes, and neutrophils utilize both oxidative and non-oxidative
methods for optimal killing of engulfed bacteria (Borregaard, 2010; Falloon & Gallin,
1986). Membrane-associated NADPH oxidases generate reactive oxygen species that are
either released into the extracellular milieu or into phagolysosomes to target both
intracellular and extracellular bacteria for oxidative killing (Borregaard, 2010; Nauseef,
2007). Moreover, phagolysosomes fuse with granules for the release of antimicrobial
peptides and proteases, including elastase, myeloperoxidase, defensins, and cathepsin G,
to enhance bacterial killing inside the vacuoles (Falloon & Gallin, 1986). The release of
cytotoxic and antimicrobial proteins into the extracellular milieu can also occur through a
cellular process termed degranulation. During neutrophil maturation, three distinct types
of granules are formed (azurophilic, specific, and tertiary) and are ultimately exocytosed
as a consequence of neutrophil activation by inflammatory stimuli during infection
(Borregaard, 2010; Falloon & Gallin, 1986). Degranulation also promotes recruitment of
adaptive immune cells by enhancing lymphocytic infiltration through chemokine release
(Nathan, 2006; Tecchio, Micheletti, & Cassatella, 2014).
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Lastly, neutrophils can undergo the release of neutrophil extracellular traps (NETs),
which are primarily composed of DNA bound to histones, enzymes, and antimicrobial
peptides (Brinkmann et al., 2004). NETs form a ‘sticky’ matrix immobilizing extracellular
bacteria from further dissemination and aiding in phagocytosis (Papayannopoulos &
Zychlinsky, 2009; Phillipson & Kubes, 2011). Trapped pathogens can also be directly
killed by the densely concentrated, chromatin-associated antimicrobial proteins and
peptides (Brinkmann et al., 2004).

1.3.2 Complement
Complement, a multifunctional group of proteins present in the blood and on cell
surfaces, is a highly regulated component of the innate immune system. Complement
activation promotes the recruitment of immune cells and recognition of pathogens through
chemotaxis and opsonization (Gros, Milder, & Janssen, 2008). Complement is activated
via three separate pathways: classical, lectin, and alternative. While activation of a distinct
complement pathway is target-specific (antigen-antibody complexes—classical pathway,
carbohydrate-lectin complexes—lectin pathway, and foreign surfaces—alternative
pathway), all three pathways converge on the cleavage of C3 and the deposition of the
protein fragment C3b on the target surface (Walport, 2001a, 2001b). C3b deposition
promotes opsonization and formation of the membrane attack complex (MAC). MAC
assembly, also known as the terminal pathway, is the sequential association of complement
proteins, C5b, C6, C7, C8, and C9, which insert into the bacterial membrane to form a pore
and mediate lysis of gram-negative bacteria (Bhakdi & Tranum-Jensen, 1988; MüllerEberhard, 1986). The cleavage of C3 and C5 leads to the release of anaphylatoxins, C3a
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and C5a, which induce inflammatory responses that promote recruitment of phagocytes to
the site of infection (Lambris et al., 2008). Phagocytes, including neutrophils and
macrophages, recognize opsonized pathogens through membrane-associated receptors
(e.g., CR1-4 and FcR); recognition by receptors prompts phagocytosis and bacterial
clearance (Zipfel & Skerka, 2009).
Over 20 soluble and surface-associated regulators control aberrant complement
activation and allow complement to discriminate between foreign and non-foreign cell
surfaces. To protect host cells from complement activation during inflammation,
complement regulators inhibit C3b deposition on ‘self’ cells or cleave deposited C3b to its
inactive form to prevent further complement activation and deposition (Zipfel & Skerka,
2009). Complement regulators can also target anaphylatoxins C3a and C5a for degradation
to dampen release of inflammatory mediators and prevent unnecessary recruitment of
immune cells (Mueller-Ortiz et al., 2009; Skidgel & Erdös, 2007). Complement regulation
functions beyond immune surveillance and facilitates neuroprotection, cellular
homeostasis, and removal of cellular debris (Ricklin, Hajishengallis, Yang, & Lambris,
2010; Walport, 2001a, 2001b). Soluble regulators are generally categorized by the
complement pathway targeted: classical and lectin pathways (C1 inhibitor and C4b-binding
protein (C4BP)), alternative pathway (factor H and properdin), and terminal pathway
(vitronectin and clusterin) (Blom, Villoutreix, & Dahlbäck, 2004a; Davis, Mejia, & Lu,
2008; Hourcade, 2008; Józsi & Zipfel, 2008; Preissner & Seiffert, 1998; Schwarz et al.,
2008). Membrane-associated regulators, including CR1, CR2, DAF, CD46, and CD59, can
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act on all three pathways of complement activation by inactivating C3 and C4 (Zipfel &
Skerka, 2009).

1.4 Bacterial immune evasion mechanisms
Bacterial pathogens have developed a multitude of parallel mechanisms that serve
to withstand environmental stressors, evade host immune defenses, and promote survival
within a host. As the first line of host defense during infection, neutrophils and complement
are common targets of bacterial evasion mechanisms (Fig. 3 and Fig. 4).

1.4.1 Neutrophil evasion
Recruitment
Chemoattractants recruit neutrophils to the site of inflammation and promote
expression of surface adhesins to allow for neutrophil extravasation across the endothelial
layer. The family of staphylococcal superantigen-like proteins (SSLs) promotes bacterial
survival by interfering with recruitment of neutrophils during infection (Thammavongsa,
Kim, Missiakas, & Schneewind, 2015). SSL5 and SSL11 interact with P-selectin
glycoprotein ligand 1 (PSGL1) on neutrophil surfaces to prevent neutrophil adherence and
extravasation through the endothelium (Bestebroer et al., 2007; Chung et al., 2007).
Furthermore, SSL5 binds G protein-coupled receptors to inhibit anaphylatoxin-mediated
activation of neutrophils and proinflammatory chemokine release (Bestebroer et al., 2007,
2009). Secretion of SSL3 and SSL10 avert neutrophil chemoattraction through association
with lymphocyte receptors, TLR2 and CXCR4, respectively (Spaan, Surewaard, Nijland,
& van Strijp, 2013; Yokoyama et al., 2012). Group A Streptococcus dampens neutrophil
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recruitment through the expression of a membrane-anchored serine protease SpyCEP that
degrades the chemokine IL-8 (Zinkernagel et al., 2008). Streptococcal secreted esterase
(Sse) and C5a peptidase A (SCPA) are secreted by the organism and inactivate C5a and
chemotactic platelet-activating factor to further suppress neutrophil recruitment (M. Liu et
al., 2012; Terao, Yamaguchi, Hamada, & Kawabata, 2006).
Phagocytosis
Neutrophils recognize antibodies, complement fragments, and pathogen associated
molecular patterns through the expression of various surface receptors that promote
neutrophil association and phagocytic uptake of bacterial invaders. Bacterial cytotoxins
play an integral role in promoting resistance to neutrophil phagocytosis and enhance
bacterial invasion. Staphylococcus aureus can escape neutrophil phagocytic vacuoles
through the expression of leukocidin LukAB (DuMont et al., 2013). Group A
Streptococcus produces streptolysin S (SLS) and streptolysin O (SLO) that initiate
neutrophil apoptosis and hinder phagocytosis (Datta et al., 2005; Timmer et al., 2009).
During pathogenesis, mutations in the two-component system, CovRS, up-regulate
streptolysin O production and boost innate immune evasion by streptococci (Sumby,
Whitney, Graviss, DeLeo, & Musser, 2006; M. J. Walker et al., 2007).
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Figure 3: Neutrophil antimicrobial functions and bacterial evasion factors.
Evasion factors expressed by pathogen bacteria that target neutrophil recruitment
(A), phagocytosis (B), the oxidative burst response/degranulation (C), and neutrophil
extracellular traps (NETs) (D). Adapted from (Serruto, Rappuoli, Scarselli, Gros, &
Van Strijp, 2010) and (Criss & Seifert, 2012).
Encapsulated pathogenic bacteria physically avoid phagocytosis by preventing
opsonization and neutrophil recognition of surface antigens. Moreover, bacterial capsules
expressed by pathogens, such as N. meningitidis, prevent phagocytosis by enhancing the
anionic properties of the bacterial surface (Jarvis & Vedros, 1987). Group A Streptococcus
produces a membrane-anchored M protein that binds complement regulators (factor H and
C4BP) and blocks opsonization to remain undetected by neutrophils (Oehmcke, Shannon,
Mörgelin, & Herwald, 2010).
Oxidative burst and degranulation
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Neutrophils contain oxidative and non-oxidative methods to effectively target and
kill intracellular and extracellular bacteria. N. gonnorhoeae porin and group A
Streptococcus streptolysin O impair stimulation of the neutrophil oxidative burst response
and suppress reactive oxygen species (ROS) generation (Uchiyama et al., 2015; Wetzler,
Blake, Barry, & Gotschlich, 1992). Streptococcal and staphylococcal superoxide
dismutases enzymatically detoxify neutrophil superoxides to prevent bacterial killing via
ROS production (Henningham, Döhrmann, Nizet, & Cole, 2015; Karavolos, Horsburgh,
Ingham, & Foster, 2003). S. aureus also synthesizes enzymes that protect the bacterium
from nitrosative stress, hydrogen peroxide, and hydroxy radicals (Cosgrove et al., 2007; G.
Y. Liu et al., 2005; Richardson, Libby, & Fang, 2008).
Bacterial resistance to neutrophil degranulation and the influx of antimicrobial
peptides is mediated by the expression of proteinases and efflux pumps that target granular
contents (Criss, Katz, & Seifert, 2009; Hagman et al., 1995; Stapels et al., 2014; Stohl,
Criss, & Seifert, 2005). Enzymatic modifications of the S. aureus peptidoglycan layer and
teichoic acids impede bactericidal activity of neutrophil antimicrobial peptides and
secreted proteases (Bera, Herbert, Jakob, Vollmer, & Götz, 2005; Ernst & Peschel, 2011;
Peschel et al., 1999).
Neutrophil extracellular traps
NET formation is considered a last effort attempt to kill extracellular bacteria by
entangling microbes in DNA meshwork, increasing proximity to antimicrobial peptides,
and facilitating phagocytosis. DNase production by streptococcal and staphylococcal
strains is a significant effector for NET dispersal and evasion (Berends et al., 2010;
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Buchanan et al., 2006). Degradation of NETs prevents entrapment and bacterial killing via
antimicrobial peptides or neutrophil phagocytosis. Beyond the release of nucleases, the S.
pneumoniae polysaccharide capsule protects against the antimicrobial effects of NET
expulsion by reducing DNA interaction (Wartha et al., 2007). As previously mentioned,
the group A Streptococcus SpyCEP peptidase targets IL-8 for degradation (Zinkernagel et
al., 2008). IL-8 chemokine secretion promotes NET production and bacterial clearance.

1.4.2 Complement evasion
Complement activation relies on a cascade of events to deposit opsonins on the
bacterial surface and promote formation of the membrane attack complex and/or
recognition by phagocytes. Microbes express a host of proteins that interrupt or impede
proper activation of complement to escape detection by the immune system (Fig. 4).

Figure 4: The complement system and evasion strategies by pathogenic bacteria.
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The three pathways of complement activation and selected bacterial evasion factors
listed near their relevant complement targets. Adapted from (Serruto et al., 2010).
Complement regulators
Acquisition of complement regulators is a common strategy for complement
evasion by bacterial pathogens, such as E. coli, N. meningitidis, H. influenzae, and S.
pneumoniae (Hallström & Riesbeck, 2010; Kugelberg, Gollan, & Tang, 2008; Lambris et
al., 2008; Thammavongsa et al., 2015). Soluble complement regulators (factor H, factor Hlike protein 1, and C4BP) are present in high concentrations in human serum, making them
readily accessible for acquisition by invading microbes. Neisserial species express multiple
and often redundant surface proteins or structures that interact with complement regulators
to promote survival in the host. N. meningitidis produces factor H-binding proteins, NspA
and fHbp, as well as the C4BP-binding protein PorA (Jarva, Ram, Vogel, Blom, & Meri,
2005; Lewis et al., 2010; Lewis, Carter, & Ram, 2012; Madico et al., 2006); N.
gonorrhoeae produces the factor H-binding protein PorB1A, which also binds C4BP along
with PorB1B (Ram et al., 2001; Ram, McQuillen, et al., 1998). The sialylated LOS
produced by N. gonorrhoeae has also been observed to interact with human factor H (Ram,
Sharma, et al., 1998).
Antigen masking
Despite the vast diversity of polysaccharide capsule structures, bacterial
encapsulation provides protection by masking surface antigens from antibody recognition
and physically preventing complement deposition on the bacterial surfaces (Achtman,
1995; Horwitz & Silverstein, 1980; Kugelberg et al., 2008; Peterson, Wilkinson, Kim,
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Schmeling, & Quie, 1978). Similarly, N. meningitidis can evade antibody detection by
mimicking host-cell surfaces with sialylated LOS and masking bacterial epitopes
(Schneider, Exley, Ram, Sim, & Tang, 2007; van Vliet et al., 2009).
Proteolytic degradation
The release of bacterial proteases or acquisition of host enzymes for antibody or
complement degradation has been readily exploited by bacteria to prevent complement
activation. Pseudomonas species prevent activation of the classical complement pathway
by inactivating or degrading immunoglobulins, C1q, and C3 to non-functional fragments
by the elastase PaE and alkaline protease PaAP (Lambris et al., 2008; Rooijakkers & van
Strijp, 2007). Group A and B streptococci express C5a peptidases that degrade C5a and
halt chemotactic signaling and proinflammatory responses (Chmouryguina, Suvorov,
Ferrieri, & Cleary, 1996). Furthermore, exotoxin B from S. pyrogenes targets complement
regulator properdin for degradation, destabilizing C3 convertases deposited on bacterial
surfaces (Tsao et al., 2006).
Professional complement evader – Staphylococcus aureus
Gram-positive bacteria passively inhibit MAC formation due to their thick
peptidoglycan cell wall; however, gram-positive bacteria can still be opsonized by
antibodies or complement fragments and targeted by phagocytic cells. Complement
evasion by S. aureus has been extensively studied due to its vast array of surface factors
that inhibit multiple complement pathways and regulators. In addition to many other
complement-targeted staphylococcal proteins, S. aureus produces staphylococcal
complement inhibitor (SCIN), which inhibits the alternative pathway C3 convertase to
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prevent C3b opsonization and release of C3a and C5a (Rooijakkers, Ruyken, et al., 2005).
Secreted proteins SSL7 and Sbi-I/Sbi-II bind to human immunoglobulins to interfere with
antibody recognition and block activation of the classical complement pathway (H. K. Kim
et al., 2012; Thammavongsa et al., 2015; Zhang, Jacobsson, Vasi, Lindberg, & Frykberg,
1998). S. aureus expresses plasminogen kinase that binds and converts endogenous
plasminogen into plasmin; on the bacterial surface, plasmin can degrade both IgG and C3
(Lähteenmäki, Kuusela, & Korhonen, 2001; Rooijakkers, van Wamel, Ruyken, van Kessel,
& van Strijp, 2005). Efb and Ecb are multi-functional staphylococcal proteins that disrupt
the C3 and C5 convertases and bind C3d (a C3b cleavage product) and factor H to prevent
complement activation and proinflammatory responses (Amdahl et al., 2013; H. Chen et
al., 2010; Jongerius et al., 2007).

1.5 Dissertation overview
Chapter 2 describes how the K. kingae polysaccharide capsule and
exopolysaccharide promote survival in the presence of human serum and active
complement by preventing antibody and opsonin deposition. Additionally, Chapter 2
demonstrates that both surface polysaccharides are necessary for full virulence of K. kingae
in an infant rat infection model. Chapter 3 examines the distinct roles of the polysaccharide
capsule and exopolysaccharide in protecting K. kingae against neutrophil-mediated killing.
Chapter 4 delves into the characterization of the exopolysaccharide locus and determines
the diversity of the exopolysaccharide in clinical isolates. Lastly, Chapter 5 summarizes
the future directions and implications of this work.
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2. Kingella kingae surface polysaccharides promote resistance to
human serum and virulence in a juvenile rat model
2.1 Introduction
The encapsulated gram-negative coccobacillus Kingella kingae is a member of the
commensal flora in the oropharynx in young children and is emerging as an important
pathogen in the pediatric population (Yagupsky et al., 2009). Recent epidemiological
studies using sensitive PCR-based diagnostics have revealed that K. kingae is a leading
cause of osteoarticular infections in young children between 6 and 36 months of age
(Chometon et al., 2007a; Yagupsky, 2014; Yagupsky et al., 2011). In addition, K. kingae
is a known cause of bacteremia and endocarditis in this population (Yagupsky, 2014;
Yagupsky et al., 2011). Following asymptomatic colonization of the upper respiratory tract,
K. kingae can breach the epithelium, enter the bloodstream, and spread to distant sites to
produce disease (Amit et al., 2013; Bidet et al., 2013; Kehl-Fie & St. Geme III, 2007;
Yagupsky et al., 2006, 2009). The mechanism by which K. kingae evades host innate
immune responses during oropharyngeal colonization, in the bloodstream, and at sites of
invasive disease is currently poorly understood.
Survival of bacteria in the bloodstream involves a complex interplay between the
organism and the innate and adaptive immune systems. The innate immune system
provides a rapid and immediate response to infection and plays an especially important role
in children, who have a relatively naïve adaptive immune system. A key component of
innate immunity in the bloodstream is the complement system, a highly regulated and
multifunctional group of circulating proteins that promote recognition of pathogens by
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immune cells through chemotaxis and opsonization and that are capable of direct killing of
bacteria (Ricklin et al., 2010; Sarma & Ward, 2011). Complement is activated via the
classical, the alternative, and the lectin pathways; all three of these pathways converge on
the deposition of the protein fragment C3b on the bacterial surface. C3b promotes
opsonization and formation of the membrane attack complex (MAC), which mediates
direct lysis of gram-negative bacteria (Ricklin et al., 2010; Sarma & Ward, 2011). Invasive
bacterial pathogens express a variety of extracellular factors that mediate resistance to
complement-mediated opsonin deposition and bacterial lysis.
Bacterial pathogens commonly express surface polysaccharides, which serve a
multitude of functions and often allow the organism to tolerate environmental stressors,
evade host immune mechanisms, and ultimately survive within the host. Capsular
polysaccharides are lipidated, surface-anchored carbohydrate chains that have been widely
shown to protect bacteria against mucosal and intravascular inflammatory responses by
preventing phagocytosis and complement-mediated lysis (Geoffroy, Floquet, Métais,
Nassif, & Pelicic, 2003; Horwitz & Silverstein, 1980; Noel, Hoiseth, & Edelson, 1992;
Peterson et al., 1978). The polysaccharide capsules of Streptococcus pneumoniae,
Haemophilus influenzae, Neisseria meningitidis, and a variety of other organisms have
been extensively studied due to their importance as virulence factors and their effective use
as vaccine antigens (Goldblatt, 2000; Hyams, Camberlein, Cohen, Bax, & Brown, 2010;
Moxon & Kroll, 1988; Swartley et al., 1997). In K. kingae, four distinct polysaccharide
capsules have been identified, designated types a, b, c, and d (Starr, Porsch, Seed, Heiss,
et al., 2016). Capsule types a and b account for greater than 95% of invasive disease isolates
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(Porsch et al., 2017; Starr, Porsch, Seed, Heiss, et al., 2016). Previous work has
demonstrated that the capsule is required for full K. kingae virulence in a juvenile rat model
of invasive disease (Starr et al., 2013; Starr, Porsch, Seed, & St. Geme III, 2016).
Bacteria can also express additional or alternative surface polysaccharides, known
as exopolysaccharides, which are secreted carbohydrate polymers that are not covalently
anchored to the bacterial membrane and hence are different from polysaccharide capsules
(Nwodo et al., 2012; Sutherland, 1982). To date, exopolysaccharides have been studied
largely in the context of bacterial biofilm formation and dispersal. In addition to expressing
a capsular polysaccharide, K. kingae produces a galactofuranose homopolymer
exopolysaccharide called the PAM galactan, which has been previously shown to have
anti-biofilm properties (Bendaoud et al., 2011; Starr et al., 2013). While a number of
bacterial polysaccharide capsules have been studied for their ability to promote evasion of
complement-mediated and neutrophil-mediated killing, understanding of the role of
exopolysaccharides in these functions is limited (Ganguly et al., 2014; Jones & Wozniak,
2017; Miajlovic et al., 2014; Mishra et al., 2012).
In this study, we found that K. kingae is highly resistant to serum killing, resulting
from the overlapping ability of the polysaccharide capsule and the exopolysaccharide to
prevent opsonin deposition and complement-mediated lysis via the classical pathway.
Elimination of both the capsular polysaccharide and the exopolysaccharide resulted in a
complete loss of virulence in juvenile rats, highlighting the critical roles of these surface
polysaccharides in K. kingae virulence.
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2.2 Methods
2.2.1 Bacterial strains and growth conditions
The strains used in this study are listed in Table 2. The parent K. kingae strain 269492 (Kehl-Fie & St. Geme III, 2007) grows on solid agar as two phenotypically stable
colony types, designated KK01 and KK03. As described in our earlier work, the KK01
and KK03 colony types differ in their density of piliation. K. kingae KK01 was used as
the wild type strain throughout this study. K. kingae strains were stored at -80°C in brain
heart infusion (BHI) broth with 20% glycerol.
E. coli strains were stored at -80°C in Luria-Bertani (LB) broth with 15% glycerol.
K. kingae strains were grown at 37°C with 5% CO2 on chocolate agar plates supplemented
with 50 µg/ml kanamycin or 1 µg/ml erythromycin, as appropriate. E. coli strains were
grown at 37°C on LB agar or in LB broth supplemented with 100 µg/ml ampicillin, as
appropriate.

Strain
Kingella kingae
KK01
PYKK98
PYKK93
PYKK58
KK146
PYKK060

Table 2: Strains and plasmids used in this study
Description
Nonspreading/noncorroding derivative of
269-492
Clonal group B isolate from case of
bacteremia, capsule type a
Clonal group P isolate from case of
bacteremia, capsule type a
Clonal group N isolate from case of septic
arthritis, capsule type b
Clonal group N isolate from case of
bacteremia, capsule type b
Clonal group D isolate from case of
endocarditis, capsule type c
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Reference
(Kehl-Fie & St.
Geme III, 2007)
Yagupsky, P.
Yagupsky, P.
Yagupsky, P.
Yagupsky, P.
Yagupsky, P.

ATCC23330

KK01csaA

Clonal group D isolate from a healthy
carrier, capsule type c
Clonal group F isolate from a healthy
carrier, capsule type d
Clonal group U isolate from a healthy
carrier, capsule type d
Contains csaA deletion

KK01pam

Contains pamABCDE deletion

KK01csaApam

Contains csaA deletion and pamABCDE
deletion
Contains the capsule synthesis locus
flanking genes and a deletion of the csaA
region
KK01SwapEmpty with csa locus
recombined

E3339
BB270

KK01SwapEmpty
KK01Swapcsa

ATCC
Yagupsky, P.
Yagupsky, P.
(Starr, Porsch,
Seed, & St.
Geme III, 2016)
(Starr et al.,
2013)
This study
(Starr, Porsch,
Seed, Heiss, et
al., 2016)
(Starr, Porsch,
Seed, Heiss, et
al., 2016)
(Starr, Porsch,
Seed, Heiss, et
al., 2016)
(Starr, Porsch,
Seed, Heiss, et
al., 2016)
(Starr, Porsch,
Seed, Heiss, et
al., 2016)
This study

KK01Swapcsb

KK01SwapEmpty with csb locus
recombined

KK01Swapcsc

KK01SwapEmpty with csc locus
recombined

KK01Swapcsd

KK01SwapEmpty with csd locus
recombined

KK01SwapEmptypam
KK01Swapcsapam

KK01SwapEmpty with pamABCDE
deletion
KK01Swapcsa with pamABCDE deletion

KK01Swapcsbpam

KK01Swapcsb with pamABCDE deletion

This study

KK01Swapcscpam

KK01Swapcsc with pamABCDE deletion

This study

KK01Swapcsdpam

KK01Swapcsd with pamABCDE deletion

This study

E. coli
DH5a

-

E. coli F φ80dlacZ∆M15 ∆(lacZYAargF)U169 deoR recA1 endA1 hsdR17(rK
+

mK ) phoA supE441 thi-1 gyrA96 relA1
H. influenzae
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This study

(Sambrook,
Fritsch, &
Maniatis, 1989)

C54

Haemophilus influenzae serotype b isolate

C54 b-

Spontaneous capsule deficient derivative
of strain C54
Description

Plasmid
E. coli
pUC19pam::ermC

pUC19 with ermC erythromycin cassette
flanked by surrounding 5’ and 3’ regions
of the pamABCDE locus

(Pichichero,
Loeb, Anderson,
& Smith, 1982)
(St. Geme &
Falkow, 1991)
Reference
(Starr et al.,
2013)

2.2.2 Strain construction
The csaA mutant, the pam mutant, and the capsule swap strains were generated as
previously described (Starr et al., 2013; Starr, Porsch, Seed, Heiss, et al., 2016; Starr,
Porsch, Seed, & St. Geme III, 2016). To generate the KK01csaApam double mutant and
the capsule swap strains containing the pam locus deletion, strains KK01csaA,
KK01Swapcsa, KK01Swapcsb, KK01Swabcsc, KK01Swapcsd, and KK01SwapEmpty
were transformed with linearized plasmid pUC19pam::ermC. Briefly, the plasmid was
purified from E. coli, linearized with NdeI, and introduced into the parental strains (csaA
mutant or swap strains) via natural transformation. Transformants were recovered on
chocolate agar plates containing 1.0 µg/ml erythromycin. Correct insertion of the gene
disruption construct was confirmed via PCR and sequencing of the deletion site. The
absence of capsule and exopolysaccharide was confirmed in strain KK01csaApam and the
capsule swap pam deletion strains using Alcian blue and silver staining as previously
described (Porsch et al., 2012; Starr et al., 2013), with the parental strains and strain KK01
as controls.
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2.2.3 Polysaccharide extraction and staining
For capsule extractions, bacteria were washed and resuspended in Tris acetate pH
5 for one hour. Cells were removed by centrifugation, and extracts were treated with
proteinase K for one hour, and then concentrated as previously described (Porsch et al.,
2012). For exopolysaccharide extractions, bacteria were resuspended in 5 ml PBS and
vortexed. Cells were removed by centrifugation, and bacterial supernatants were treated
with proteinase K for one hour, and then concentrated as previously described (Porsch et
al., 2012).
Aliquots of supernatant and purified capsule from K. kingae derivatives were
separated on 7.5% or 10% SDS-PAGE gels, respectively. For supernatant samples, SDSPAGE gels were treated first with silver staining and subsequently with Alcian blue
staining. For purified capsule samples, SDS-PAGE gels were treated with Alcian blue
staining. For silver staining, gels were treated as previously described (J. S. Kim, Reuhs,
Rahman, Ridley, & Carlson, 1996). For Alcian blue staining, gels were stained with
0.125% Alcian blue as previously described (Porsch et al., 2012).

2.2.4 Serum bactericidal assays
K. kingae strains and E. coli strain DH5a were grown on chocolate agar plates and
then resuspended in PBS containing 0.1% gelatin (PBS-G). H. influenzae strains were
grown on chocolate agar plates overnight, resuspended in BHI with 3.5 µg/ml NAD and
0.1% lysed horse blood to an OD600 of 0.2, and were grown to an OD600 between 0.6-0.8
shaking at 250 rpm. Samples were diluted in PBS-G to obtain a final inoculum of
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approximately 4.0 x 103 cfu/0.1 ml. The respective inocula were mixed with pooled NHS
(Immucor, Norcross, GA) or HI-NHS (prepared by incubating NHS at 56°C for 20 min)
diluted in PBS-G, as appropriate, and incubated for various time points at 37°C with 5%
CO2. Complement activity was assessed and confirmed using a total hemolytic assay as
previously described (Costabile, 2010). Serial dilutions of the inoculum and reaction
samples were plated on chocolate agar plates and incubated overnight at 37°C with 5%
CO2 to determine cfu counts (limit of detection for plating: 20 cfu). To perform classical
pathway inhibition assays, samples were incubated with EGTA at a final concentration of
5 mM and supplemental MgCl2 at a final concentration of 9 mM prior to introduction of
NHS.

2.2.5 Flow cytometry analysis
K. kingae strains were grown on chocolate agar plates, resuspended to an OD600 0.8
in PBS, pelleted, and resuspended in 4% paraformaldehyde in PBS for fixation. After
incubation for 20 min at room temperature (RT), bacteria were washed with Tris-buffered
saline (TBS) and resuspended in PBS. We modified previously described protocols to
detect bacterial opsoninization (Agarwal, Vasudhev, DeOliveira, & Ram, 2014; Mishra et
al., 2012). Briefly, fixed bacteria were incubated with 20% NHS as the source of C3b or
1% NHS as the source of C4b. Samples were incubated with gentle agitation for 15 min at
RT, washed with PBS, and resuspended in TBS containing 50 mM EDTA and 0.1% bovine
serum albumin (BSA). Fixed bacteria were incubated with or without a 1:250 dilution of a
mouse anti-human C3b monoclonal antibody (Thermo Fisher, Rockford, IL) or a 1:250
dilution of a rabbit anti-human C4b monoclonal antibody (Abcam, Cambridge, MA) for 1
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hr at RT. Samples were washed twice in PBS, resuspended in PBS containing 0.1% BSA,
and incubated with a 1:200 dilution of a rabbit anti-mouse IgG DyLight 488-conjugated
antibody (Rockland, Limerick, PA) or a 1:200 dilution of a goat anti-rabbit IgG DyLight
488-conjugated antibody (Rockland) for 45 min at RT as appropriate. Bacteria were
washed, resuspended in PBS, and stained with propidium iodide (Biotium, Fremont, CA)
for flow cytometry analysis. For classical pathway inhibition assays, samples were
incubated with EGTA at a final concentration of 5 mM and supplemental MgCl2 at a final
concentration of 9 mM prior to introduction of NHS.
For human IgG and human IgM surface deposition analysis, bacteria were fixed,
resuspended in TBS containing 50 mM EDTA and 0.1% BSA, and then incubated with
PBS as a control or 1% HI-NHS as a source of human IgG and human IgM. After gentle
agitation for 1 hr at RT, samples were washed twice with PBS, resuspended in PBS
containing 0.1% BSA, and then incubated with a 1:200 dilution of a goat anti-human IgG
(H&L) DyLight 488-conjugated antibody (Rockland) or a 1:200 dilution of a goat antihuman IgM (mu chain) DyLight 488-conjugated antibody (Rockland) for 45 min at RT.
Bacteria were washed, resuspended in PBS, and stained with propidium iodide (Biotium)
for flow cytometry analysis. Flow cytometry assays were performed using an Accuri C6
instrument (BD Biosciences, San Jose, CA).

2.2.6 K. kingae-specific serum antibody detection
Serum antibodies reactive to K. kingae whole cell and outer membrane fractions
were determined by Western blotting. Total membranes were recovered by centrifugation
of cleared bacterial sonicates and outer membrane fractions were isolated on the basis of
40

sarkosyl insolubility. The whole cell and outer membrane fractions were separated on a
7.5% SDS-PAGE gel, transferred to nitrocellulose, and probed with 2% HI-NHS, followed
by an anti-human Ig– horseradish peroxidase (HRP)-conjugated secondary antibody
(Sigma, St. Louis, MO) at a dilution of 1: 5,000. The blot was developed by using a
chemiluminescent substrate.

2.2.7 Juvenile rat infection model
Nursing 5-day-old Sprague-Dawley rat pups (Charles River Laboratories,
Wilmington, MA) were injected via the intraperitoneal route with 0.1 ml PBS alone
(control) or 10 µg of CVF (Complement Technology, Tyler, TX) in 0.1 ml PBS. K. kingae
strains were grown on chocolate agar for 18 hrs, and the bacteria were swabbed from plates
and resuspended in PBS to a final density of 1 x 108 cfu/ 0.1 ml. While the in vitro serum
bactericidal assays used 1 x 103 cfu to conserve human serum, 1 x 108 cfu was the necessary
infectious dose in vivo to consistently generate invasive disease in rat pups with strain
KK01. Three hours post-CVF injection, rat pups were injected via the intraperitoneal route
with 0.1 ml of the appropriate bacterial suspension or 0.1 ml of PBS alone (control). Rat
pups were injected using a 27 1/2-gauge needle and then returned to their cage with a
lactating dam. The experimental and control groups were housed separately with a lactating
dam and were monitored for mortality and signs of illness every six hours for the first 30
hrs and then twice daily for a total of five days. Animals found to be moribund were
euthanized by using CO2 inhalation followed by secondary decapitation.
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2.2.8 Ethics statement
All animal experiments described within were conducted in accordance with the
Animal Welfare Act, the Public Health Service Policy on Humane Care and Use of
Laboratory Animals from the U.S. Department of Health and Human Services, and the
recommendations in the Guide for the Care and Use of Laboratory Animals of the National
Research Council. The Children’s Hospital of Philadelphia animal research facilities have
full accreditation from the Association for Assessment and Accreditation of Laboratory
Animal Care (AAALAC) International. The animal procedures were approved by the
Children’s Hospital of Philadelphia Institutional Animal Care and Use Committee
(IACUC) under protocol IAC 16-001050.

2.2.9 Statistical analysis
Statistical analyses were performed with GraphPad Prism version 7.0a for Mac
(GraphPad Software, San Diego, CA) where P < 0.05 was considered statistically
significant. Unpaired Student’s t-test was performed as appropriate. Mortality rates were
calculated using the log-rank (Mantel-Cox) test for significance.

2.3 Results
2.3.1 K. kingae is highly resistant to complement-mediated lysis.
The ability of K. kingae to survive in the bloodstream in young children suggests
that the organism is capable of evading the host innate immune response. To test the
capacity of K. kingae to evade complement-mediated lysis, we performed serum
bactericidal assays using normal human serum (NHS) as a source of active complement or
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heat-inactivated (HI)-NHS as a source of inactive complement. K. kingae strain KK01 at
an inoculum of 1.0 x 103 cfu (colony forming units) was incubated for 1 hr with serum
concentrations ranging from 2% to 50% (Fig. 5A), using E. coli strain DH5a as a serumsensitive control. To assess serum sensitivity, a survival ratio was calculated, dividing the
number of cfu recovered from NHS by the number of cfu recovered from HI-NHS. The
limit of detection for plating was 20 cfu, which enabled detection of up to a 98% reduction
in bacterial survival. At low NHS concentrations, there was no killing of strain KK01 but
complete killing of strain DH5a (Fig. 5A). At a NHS concentration of 50%, strain KK01
had a survival ratio of approximately 0.80 (cfu in NHS divided by cfu in HI-NHS) (Fig.
5A). As expected, HI-NHS had no effect on survival of strain KK01 or strain DH5a at any
serum concentration. These results demonstrate that K. kingae exhibits high-level
resistance to complement-mediated lysis.

2.3.2 Surface polysaccharides prevent complement-mediated lysis of K.
kingae.
To determine the role of the K. kingae surface polysaccharides (the polysaccharide
capsule and the exopolysaccharide) in serum resistance, we performed serum bactericidal
assays using strain KK01 mutants deficient in expression of the polysaccharide capsule,
the exopolysaccharide, or both, using strain KK01csaA (a capsule-deficient mutant lacking
the csaA capsule synthesis gene) (Starr, Porsch, Seed, & St. Geme III, 2016), strain
KK01pam (an exopolysaccharide-deficient mutant lacking the pamABCDE galactan
exopolysaccharide synthesis operon) (Starr et al., 2013), and strain KK01csaApam (a
double mutant lacking both capsule and exopolysaccharide synthesis genes). Serum
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bactericidal assays were performed as described above using 50% serum for 1 hr and using
E. coli strain DH5a as a serum-sensitive control. In addition, isogenic encapsulated and
non-encapsulated derivatives of H. influenzae strain C54 (designated [+] for encapsulated
and [–] for non-encapsulated strains) were included as controls to demonstrate the
importance of the polysaccharide capsule in serum resistance for another gram-negative
bacterium. Deletion of csaA, pamABCDE, or both csaA and pamABCDE resulted in no
growth defects on solid agar and had no effect on survival in the presence of 50% HI-NHS.
KK01 and the mutant derivatives maintained stable bacterial counts over the course of the
1 hr assay in HI-NHS (data not shown). Survival in NHS by the capsule mutant (strain
KK01csaA) or the exopolysaccharide mutant (strain KK01pam) was not affected and was
similar to the survival of wild-type strain KK01 (Fig. 5B). In contrast, survival in NHS by
the double mutant lacking both capsule and exopolysaccharide (strain KK01csaApam) was
markedly reduced, with a survival ratio of less than 0.35 (P < 0.05, Fig. 5B). While the
absence of both capsule and exopolysaccharide resulted in reduced resistance to serum,
survival of strain KK01csaApam was not reduced to undetectable levels, as observed with
the serum sensitive controls E. coli DH5a and H. influenzae C54 b-.

44

Figure 5: K. kingae is highly resistant to the bactericidal effects of complement present
in pooled normal human serum, and elimination of both surface polysaccharides
decreases serum resistance in K. kingae.
K. kingae strain KK01 and E. coli strain DH5a (~103 CFU) were incubated with 2%,
5%, 15%, 25%, or 50% NHS or HI-NHS for 1 h (A). K. kingae strains KK01,
KK01csaA, KK01pam, and KK01csaApam, E. coli strain DH5a, and H. influenzae (H.
flu) strains C54+ (encapsulated) and C54- (nonencapsulated) were incubated with
50% NHS or 50% HI-NHS for 1 h (B). The survival ratio was calculated by dividing
the NHS CFU counts by the HI-NHS CFU counts. Abbreviations: csaA, KK01csaA;
pam, KK01pam; csaApam, KK01csaApam. A total of three biological replicates were
performed (n = 3). Statistical significance was determined with an unpaired Student’s
t test, and the error bars represent the standard error of the mean. *, P < 0.05.
These results establish that elimination of both capsule and exopolysaccharide is
critical for increased complement-mediated lysis and demonstrate the potent ability of K.
kingae to evade complement-mediated lysis.

2.3.3 Opsonin deposition is increased in the absence of surface
polysaccharides.
Elimination of the polysaccharide capsule in other organisms has been shown to
expose bacterial surface factors and promote antibody recognition and thus activation of
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complement via the classical pathway (Domenico, Tomas, Merino, Rubires, & Cunha,
1999; Howard & Glynn, 1971; Tomás, Camprubi, Merino, Davey, & Williams, 1991). To
determine whether K. kingae-specific antibodies were present in HI-NHS, Western blot
analyses of whole cell lysates and outer membranes were performed using HI-NHS as the
primary antibody. Human serum immunoglobulins reacted with proteins present in K.
kingae whole cell and outer membrane fractions (Fig. 6) To further investigate whether the
capsule and/or the exopolysaccharide prevents antibody binding, we performed flow
cytometry assays to determine relative levels of IgG and IgM deposition on the K. kingae
surface after incubation with HI-NHS as the source of antibodies or with secondary
antibody alone as a control. There was negligible fluorescence after the incubation with
the secondary antibody alone (Fig. 7A and 7B; gray bars), thus demonstrating the absence
of non-specific binding of the secondary antibody. No significant difference in deposition
was observed between strain KK01 and the single mutant strains KK01csaA and KK01pam
after incubation with HI-NHS (Fig. 7A and 7B). In contrast, there was a statistically
significant increase in deposition of both IgG and IgM on the surface of strain
KK01csaApam, consistent with our observations regarding serum sensitivity (Fig. 7A and
7B).
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Figure 6: Human IgG reactivity to K. kingae whole cell and outer membrane
fractions.
Whole-cell (WC) and outer membrane (OM) fractions were purified from K. kingae
strains KK01, KK01csaA, KK01pam, and KK01csaApam. Samples were run on a
7.5% SDS-PAGE gel, probed with 2% HI-NHS, and followed by an anti-human Ig–
HRP-conjugated secondary antibody. Molecular sizes in kDa.
The constant region of IgG and IgM provides a platform for the initiation of the
complement cascade (Duncan & Winter, 1988; Gadjeva et al., 2008; Perkins, Nealis,
Sutton, & Feinstein, 1991; Zlatarova et al., 2006). To determine whether antibody
deposition activates the classical pathway and leads to activation of the terminal pathway,
we performed flow cytometry assays to measure the deposition of C4b and C3b, two welldocumented opsonins and products of complement activation, on the bacterial surface. As
shown in Fig. 7C and 7D, there was no significant difference in binding of C4b and C3b to
strain KK01 and the single mutant strains KK01csaA and KK01pam. In contrast, there was
a statistically significant increase in C4b and C3b deposition on strain KK01csaApam,
47

consistent with the increase in antibody deposition and serum sensitivity observed with this
strain (Fig. 7C and 7D).
These data suggest that survival of strains KK01, KK01csaA, and KK01pam in
NHS is due in part to reduced antibody deposition and the resultant absence of activating
complement fragments on the bacterial surface. Elimination of both the polysaccharide
capsule and the exopolysaccharide on the bacterial surface results in increased opsonin
deposition, promoting complement activation.

Figure 7: Opsonin deposition increases in the surface polysaccharide-deficient
mutant.
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Binding of IgG (A), IgM (B), C3b (C), or C4b (D) to the bacterial surface was
determined using flow cytometry. Cells were stained with propidium iodine (PI) prior
to analysis; 30,000 propidium iodine-positive events per biological replicate were
analyzed, and a total of three biological replicates were performed (n = 3). The
percentages represent events that registered as Alexa Fluor 488 positive (AF-488+).
Black bars, HI-NHS (A and B) or NHS (C and D); gray bars, secondary antibodyonly controls (these bars are negligible in size due to the low signal). Abbreviations:
csaA, KK01csaA; pam, KK01pam; csaApam, KK01csaApam. Statistical significance
was determined with an unpaired Student’s t test, and the error bars represent the
standard error of the mean. *, P < 0.05.

2.3.4 Inhibition of the classical pathway when surface polysaccharides are
absent restores serum survival and decreases opsonin deposition.
The deposition of IgG and IgM on the bacterial surface prompts complement
activation via the classical pathway. Ca2+ is considered necessary to maintain the integrity
of the C1 complex, which associates with the Fc region of antigen-bound IgG or IgM and
initiates the complement cascade (Bryant & Jenkins, Jr., 1968; Gadjeva et al., 2008). The
presence of EGTA in serum resistance assays chelates Ca2+ and thereby inhibits classical
pathway activation, and the concomitant addition of Mg2+ preserves the alternative
pathway (Des Prez, Bryan, Hawiger, & Colley, 1975).
To elucidate the importance of classical pathway activation in serum killing of
strain KK01csaApam, we performed serum bactericidal assays in the presence of EGTA +
Mg2+. As expected, survival of strains KK01, KK01csaA, and KK01pam was not
influenced by the introduction of 9 mM Mg2+ alone, 5 mM EGTA alone, or 9 mM Mg2+ +
5 mM EGTA (Fig. 8A). Conversely, the survival ratio of strain KK01csaApam in the
presence of either EGTA alone or EGTA + Mg2+ were restored to levels similar to the
survival ratio of strains KK01, KK01csaA, and KK01pam (Fig. 8A). As anticipated, the
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presence of Mg2+ alone had no effect on the survival ratio of strain KK01csaApam (Fig.
8A).

Figure 8: Inhibition of the classical pathway restores survival and reduces C3b
deposition in the surface polysaccharide-deficient mutant.
Serum survival was assessed with either 50% NHS alone, 50% NHS plus 9 mM Mg2+,
50% NHS plus 5 mM EGTA, 50% NHS plus 9 mM Mg2+ and 5 mM EGTA, or 50%
HI-NHS for 1 h (A). The survival ratio was calculated by dividing the NHS CFU
counts by the HI-NHS CFU counts. K. kingae strains were fixed and incubated for 15
min in medium alone, in medium containing 20% NHS, or in medium containing 20%
NHS plus 9 mM Mg2+ and 5 mM EGTA (B). Binding of C3b (n = 3) to the bacterial
surface was determined using flow cytometry, and 30,000 propidium iodine-positive
events per experiment were analyzed. The percentages represent events that
registered as Alexa Fluor 488 positive. Black bars, NHS; white bars, NHS plus 9 mM
Mg2+ and 5 mM EGTA; gray bars, secondary antibody-only control. Abbreviations:
csaA, KK01csaA; pam, KK01 pam; csaApam, KK01 csaApam. Statistical significance
was determined with an unpaired Student’s t test, and the error bars represent the
standard error of the mean. n.s., not significant; *, P < 0.05.
In order to confirm that chemical inhibition of the classical pathway via EGTA
prevents complement activation, flow cytometry assays were performed to determine the
percentage of C3b deposition on the surface of K. kingae in the presence of EGTA + Mg2+.
As shown in Fig. 8B, no significant differences in C3b deposition were observed between
strains KK01, KK01csaA, and KK01pam in the presence or absence of EGTA + Mg2+. In
50

contrast, there was a significant decrease in C3b deposition on strain KK01csaApam when
this strain was incubated in NHS containing EGTA + Mg2+ (Fig. 8B). C3b deposition on
strain KK01csaApam in NHS containing EGTA + Mg2+ mirrored the C3b deposition on
strain KK01csaApam in media alone (Fig. 8B). Taken together, these data provide further
support that the classical complement pathway is activated in the absence of K. kingae
surface polysaccharides.

2.3.5 The four distinct capsule types of K. kingae promote serum survival
in isogenic strains.
To date, a total of four distinct capsule types have been identified in diverse
collections of K. kingae clinical isolates, including type a ([3)-β-GalpNAc-(1à5)-β-Kdop(2à]), type b ([6)-α-D-GlcpNAc-(1à5)-β-(8-OAc)Kdop-(2à]), type c ([3)-β-D-Ribf(1à2)-β-D-Ribf-(1à2)-β-D-Ribf-(1à4)-β-Kdop-(2à]), and type d ([P-(Oà3)[β-DGalp-(1à4)]-β-D-GlcpNAc-(1à3)-α-D-GlcpNAc-1-]) (Porsch et al., 2017; Starr et al.,
2013; Starr, Porsch, Seed, Heiss, et al., 2016; Starr, Porsch, Seed, & St. Geme III, 2016).
The prototype strain KK01 used in this study expresses the type a capsule. To assess
whether the four capsule types have different abilities to protect the organism against
complement-mediated lysis, we performed bactericidal assays on isogenic derivatives of
strain KK01pam expressing either capsule type a (strain KK01Swapcsa), capsule type b
(strain KK01Swapcsb), capsule type c (strain KK01Swapcsc), or capsule type d (strain
KK01Swapcsd) (Starr, Porsch, Seed, Heiss, et al., 2016). As shown in Fig. 9A, all four
capsule types were associated with a survival ratio of 0.80, similar to the survival ratio of
strain KK01. These data suggest that the presence of any of the four K. kingae capsule
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types is protective and is adequate for promoting serum resistance in the absence of
exopolysaccharide in vitro.

Figure 9: Specific capsule types do not dictate serum sensitivity in K. kingae clinical
isolates.
K. kingae strains (~103 CFU) were incubated with either 50% NHS or 50% HI-NHS
for 1 h. The survival ratio was calculated by dividing the CFU counts in NHS by the
CFU counts in HI-NHS for isogenic derivatives of strain KK01pam (A) or clinical
isolates of K. kingae (B). Abbreviations: Empty, nonencapsulated strain
KK01SwapEmptypam; csa, capsule type a KK01Swapcsapam; csb, type b
KK01Swapcsbpam; csc, type c KK01Swapcscpam; csd, type d KK01Swapcsdpam; 98,
K. kingae clinical isolate PYKK98; 93, K. kingae clinical isolate PYKK93; 58, K.
kingae clinical isolate PYKK58; 46, K. kingae clinical isolate KK146; 60, K. kingae
clinical isolate PYKK60; 30, K. kingae clinical isolate ATCC 23330; 39, K. kingae
clinical isolate E3339; 70, K. kingae clinical isolate BB270. A total of three biological
replicates were performed (n = 3). Statistical significance was determined with an
unpaired Student’s t test, and the error bars represent the standard error of the mean.
*, P < 0.05.

2.3.6 K. kingae clinical isolates show moderate to high levels of serum
resistance.
Serum resistance plays an important role in pathogenicity and has been shown to
be variable from strain to strain in other bacterial species. To determine the variability of
serum resistance across K. kingae clinical isolates, we performed serum bactericidal assays
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on eight clinical isolates that represented all four capsular groups and included both
invasive and healthy carrier isolates (Fig. 9B, Table 2). Additionally, the eight clinical
isolates contain the pam locus and produce exopolysaccharide. K. kingae strains PYKK98,
KK146, ATCC23330, and BB270 showed high levels of serum resistance, with a survival
ratio of approximately 0.80 (Fig. 9B), while strains PYKK93, PYKK58, PYKK60, and
E3339 showed moderate levels of serum resistance, with survival ratios between 0.40 and
0.60 (Fig. 9B). The results demonstrate that the clinical isolates tested were resistant to
human serum; however, there was no consistent distinction in level of susceptibility in
relation to capsule type or clinical site of isolation.

2.3.7 Capsule and exopolysaccharide are required for full K. kingae
virulence in a juvenile rat infection model.
Given the importance of the capsular polysaccharide and exopolysaccharide in
protecting K. kingae from the bactericidal effects of human serum in vitro, we sought to
elucidate the role of these factors in vivo. To examine the role of the K. kingae surface
polysaccharides in virulence and to determine the influence of complement in limiting
infection in vivo, we modified a previously described juvenile rat infection protocol (Starr,
Porsch, Seed, & St. Geme III, 2016). Briefly, we injected 5-day-old Sprague-Dawley rat
pups via the intraperitoneal (i.p.) route with either phosphate-buffered saline (PBS) alone
or PBS with 10 ng of cobra venom factor (CVF), which forms a complex with complement
components factor B and factor D and creates a convertase that depletes C3 and C5 to
undetectable levels in the serum (Bauman, 1978; Van den Berg, Aerts, & Van Dijk, 1991).
CVF has been used previously in different animal models, including juvenile rats, to
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successfully deplete complement in vivo (Kauppi-Korkeila, van Alphen, Madore, Saarinen,
& Käyhty, 1996; Till, Morganroth, Kunkel, & Ward, 1987; Van den Berg et al., 1991).
Three hours post injection with PBS alone or PBS with CVF, the rat pups were injected
i.p. with 1 x 108 cfu of strain KK01, strain KK01csaA, strain KK01pam, or strain
KK01csaApam, using PBS as a control (Fig. 10A and 10B).
Among the rat pups that did not receive pretreatment with CVF, all that were
infected with strain KK01 succumbed to infection, with a median survival of 12 hrs (Fig.
10A). At five days post-infection, survival among pups infected with strain KK01csaA was
29% (p < 0.0001, Fig. 10A), and survival among pups infected with strain KK01pam was
53% (p < 0.0001, Fig. 10A). In contrast, all pups injected with strain KK01csaApam were
alive and healthy at five days post-infection, similar to pups injected with PBS alone (p <
0.0001, Fig. 10A). These results suggest that elimination of either capsule or
exopolysaccharide results in reduced virulence of K. kingae and that elimination of both
capsule and exopolysaccharide results in an avirulent strain.
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Figure 10: Surface polysaccharides are required for full K. kingae virulence in a rat
infection model.
Five-day-old Sprague-Dawley rats were injected via the intraperitoneal (i.p.) route
with either 0.1 ml PBS (A) or 10 µg CVF in 0.1 ml PBS (B). The graphs plot KaplanMeyer survival curves for rats subsequently i.p. injected with 0.1 ml PBS or 1 x 108
CFU of the KK01 strains in PBS. Data are for 17 (A) and 10 (B) animals infected with
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each strain and 15 (A) and 9 (B) animals injected with PBS. Abbreviations: csaA,
KK01csaA; pam, KK01pam; csaApam, KK01csaApam.
Among pups that received CVF pretreatment, all infected with strain KK01, strain
KK01csaA, strain KK01pam, or strain KK01csaApam succumbed to infection within 12
hrs (Fig. 10B). All pups injected with PBS alone after CVF pretreatment survived five days
post-infection (Fig. 10B). These results suggest that resistance to complement via the
polysaccharide capsule and the exopolysaccharide is critical for K. kingae virulence in
juvenile rats.

2.4 Discussion
Kingella kingae is a common commensal organism in the oropharynx and is an
emerging pediatric pathogen that represents a leading etiology of joint and bone infections
in young children (Chometon et al., 2007a; Yagupsky, 2014; Yagupsky et al., 2011). This
organism causes disease by breaching the respiratory epithelium, invading the
bloodstream, and disseminating to distant sites (Amit et al., 2013; Bidet et al., 2013; KehlFie & St. Geme III, 2007; Yagupsky et al., 2006, 2009). In order to survive in the
intravascular environment and then disseminate, the organism must evade innate immune
mechanisms.
Our initial findings revealed that K. kingae is highly resistant to the bactericidal
effects of complement present in human serum. Further examination revealed that the
presence of either the capsule or the exopolysaccharide alone was sufficient to fully prevent
opsonin deposition and completely protect K. kingae against complement-mediated killing,
a novel observation. Elimination of both the capsule and the exopolysaccharide was
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required for efficient binding of opsonins (IgG, IgM, C4b, and C3b) to the bacterial surface
and for significant complement-mediated killing in vitro. Abrogation of the classical
complement pathway in vitro restored survival of the capsule/exopolysaccharide double
mutant, clarifying the mechanism by which these surface polysaccharides promote survival
in human serum. In agreement with our in vitro data, elimination of both the capsule and
the exopolysaccharide rendered K. kingae completely avirulent, abolishing morbidity and
mortality in the juvenile rat infection model. To confirm that the attenuation of strain
KK01csaApam in vivo was a consequence of efficient activation of complement, pups were
injected with CVF to eliminate complement. As predicted, the resulting complement
deficiency was associated with an increase in virulence of all K. kingae strains, including
strain KK01csaApam.
In recent years, a number of reports have described bacterial factors associated with
evasion of complement activity in non-encapsulated organisms (Del Tordello, Vacca, Ram,
Rappuoli, & Serruto, 2014; Griffiths et al., 2011; Hallström, Blom, Zipfel, & Riesbeck,
2009; Ho, Ram, Nelson, Bonthuis, & Smith, 2007; Murphy, Kirkham, & Lesse, 2006).
However, bacterial polysaccharide capsules generally predominate as the most potent
mechanism of bacterial resistance to complement-mediated serum killing, as highlighted
by studies of H. influenzae, N. meningitidis, and E. coli. In N. meningitidis, transposon
mutagenesis and large-scale analysis of the genome searching for genes contributing to
serum resistance identified only genes involved in polysaccharide capsule or
lipooligosaccharide synthesis (Geoffroy et al., 2003). Consistent with the conclusion that
the polysaccharide capsule is important for N. meningitidis serum resistance, almost all
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meningococcal isolates recovered from blood are encapsulated, while 30-70% of carrier
isolates are non-encapsulated (Ala’Aldeen et al., 2000; Kugelberg et al., 2008; van Deuren
et al., 2000). Similarly, in H. influenzae, loss of capsule reduces or eliminates serum
resistance and overexpression of the serotype b capsule synthesis genes due to duplication
events promotes greater serum resistance (Noel, Brittingham, Granato, & Mosser, 1996;
Noel et al., 1992; Swift, Moxon, Zwahlen, & Winkelstein, 1991). In this study, we
observed that non-encapsulated K. kingae exhibits high levels of serum resistance in vitro,
similar to the serum resistance of wild-type K. kingae, underscoring the importance of the
exopolysaccharide.
In considering our observation that the K. kingae capsule and exopolysaccharide
play crucial and apparently redundant roles in serving to prevent IgG, IgM, C4b, and C3b
deposition on the bacterial surface and resultant bacterial lysis, it is noteworthy that the
capsule is tethered to the bacterial surface via a lipid anchor and the exopolysaccharide is
unanchored. We presume that the exopolysaccharide is loosely associated with the
bacterial surface, blocking access of opsonins. In earlier work, we observed that the
exopolysaccharide can be released from the bacterial surface by resuspending bacteria in
PBS and vigorously shaking, consistent with a non-covalent mechanism of association
(Starr et al., 2013). The nature of the association and the balance between surfaceassociated and released exopolysaccharide during natural infection are currently unknown.
Exopolysaccharides in other bacterial species have been studied primarily as major
contributors to the formation and dispersal of biofilms (Cerning, 1991; De Vuyst &
Degeest, 1999; Flemming et al., 2007; Nwodo et al., 2012). Exopolysaccharide function
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depends on the polymer structure and composition and has been studied related to
adherence, bacterial cell aggregation, water retention, and nutrition (Flemming et al., 2007;
Flemming & Wingender, 2002; Nwodo et al., 2012). Few studies have characterized
exopolysaccharides in the context of inhibiting complement deposition and subsequent
complement and/or leukocyte evasion (Ganguly et al., 2014; Jones & Wozniak, 2017;
Miajlovic et al., 2014; Mishra et al., 2012). In Pseudomonas aeruginosa, expression of the
Psl exopolysaccharide serves to protect the organism from neutrophil antimicrobial
functions; however, Psl does not play a role in evasion of complement-mediated lysis in
vitro and has been studied only in the context of capsule-deficient organisms, thus
contrasting with our studies of K. kingae (Mishra et al., 2012). Like K. kingae,
extraintestinal pathogenic Escherichia coli (ExPEC) produces two surface polysaccharides
that contribute to serum resistance, namely, a group 2 polysaccharide capsule and an
exopolysaccharide called colonic acid (Miajlovic et al., 2014). However, while colanic acid
is important for evasion of complement-mediated killing, the absence of the polysaccharide
capsule renders ExPEC sensitive to serum even in the presence of colanic acid, suggesting
that the exopolysaccharide alone is not sufficient for mediating serum resistance and thus
again contrasting with K. kingae (Miajlovic et al., 2014). In K. kingae, the level of
protection against complement activation and complement-mediated killing provided by
the exopolysaccharide mimics the protection provided by the polysaccharide capsule. Thus
far, two exopolysaccharide structures have been described in K. kingae: à3)-β-Galf(1à5)-β-Galf-(1à and à5)-β-Galf-(1à (Bendaoud et al., 2011; Starr et al., 2013). It has
been reported that biofilm formation and dispersal of K. kingae clinical strain PYKK181
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is dependent on the PAM galactan exopolysaccharide (Bendaoud et al., 2011). In this study,
we have shown that the PAM galactan produced by K. kingae strain KK01 prevents
opsonin deposition and complement activation, providing evidence for a novel function of
the K. kingae exopolysaccharide.
In K. kingae, four distinct polysaccharide capsules have been identified, designated
types a, b, c, and d. Using isogenic derivatives of strain KK01pam, all four capsule types
were associated with a survival ratio similar to the survival ratio for strain KK01. These
data suggest that the presence of any naturally occurring K. kingae capsule type is adequate
to protect KK01pam against serum killing under our in vitro conditions. In addition, eight
clinical isolates representing all four capsular groups and including both invasive and
healthy carrier isolates were assessed for serum resistance. Interestingly, these isolates
exhibited moderate to high levels of serum resistance, with no consistent distinctions in
level of susceptibility in relation to capsule type or clinical site of isolation. The variability
in serum survival ratio among the different clinical isolates could be due to strain-to-strain
variation in the quantity of capsule and/or exopolysaccharide. Despite the contributions of
capsule and exopolysaccharide to serum resistance, the capsule and exopolysaccharide
double mutant remained relatively resistant to human serum, with a survival ratio that was
reduced to ~40% of the level in the parent strain (Fig 5B). This observation highlights the
presence of additional factors deployed by K. kingae for innate immune evasion and may
be another explanation for the variability of serum resistance observed in the clinical
isolates.
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While our in vitro serum resistance experiments suggest no differences in
resistance between the wild type strain and the single mutant strains lacking capsule or
exopolysaccharide, our in vivo studies established that each surface polysaccharide plays a
role in promoting virulence in juvenile rats. Elimination of either capsule or
exopolysaccharide resulted in reduced virulence, including a lower mortality rate and
delayed mortality. This finding suggests that perhaps capsule and/or exopolysaccharide
play a role in virulence beyond protecting against humoral immunity in vivo; alternatively,
serum sensitivity in vitro may be unobservable in the absence of a single surface
polysaccharide. Along these lines, polysaccharide capsules and exopolysaccharides have
been implicated in both promoting and dampening host inflammatory responses. The
zwitterionic capsular polysaccharide A from Bacteriodes fragilis, the gut microfloral
commensal, is implicated in mediating development of the host immune system through
induction of CD4+ maturation and by promoting a balanced Th1/Th2 response in mice
(Surana & Kasper, 2012). Interestingly, Totté et al. have reported that a galactan
homopolysaccharide in Mycoplasma mycoides subsp. mycoides similar to the K. kingae
exopolysaccharide binds TLR2 and promotes the production of the anti-inflammatory
cytokine IL-10 (Totté et al., 2015). Further work is necessary to elucidate the
immunoregulatory potential of the K. kingae surface polysaccharides both in vitro and in
vivo.
In conclusion, both the polysaccharide capsule and the exopolysaccharide of K.
kingae play a crucial role in preventing opsonin deposition and complement-mediated
killing, presumably facilitating intravascular survival and resulting in enhanced virulence
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in vivo. These results highlight an underrecognized function of a bacterial
exopolysaccharide and provide important information that may facilitate development of a
polysaccharide-based vaccine against K. kingae.
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3. Kingella kingae surface polysaccharides promote resistance
to neutrophil phagocytosis and killing
3.1 Introduction
Kingella kingae, a gram-negative coccobacillus, is a common commensal organism
in the oropharynx of young children (Yagupsky et al., 2009). Despite being an oral
commensal, K. kingae is a primary cause of osteoarticular infections and a common
etiology of bacteremia in children between 6 and 36 months of age (Chometon et al.,
2007b; Yagupsky, 2014; Yagupsky et al., 2011). Recent studies have elucidated K. kingae
surface and secreted factors that promote virulence via adherence to epithelial cells,
cytotoxicity, and immune evasion (Chang et al., 2014; Kehl-Fie et al., 2008; Kehl-Fie &
St. Geme III, 2007; Maldonado et al., 2011; Muñoz et al., 2018; Porsch et al., 2012).
To colonize the oropharynx and survive in the hostile intravascular environment,
K. kingae must evade innate immunity. K. kingae produces a polysaccharide capsule and a
galactan homopolymer exopolysaccharide, both of which have been demonstrated to
contribute to virulence in an infant rat infection model (Muñoz et al., 2018; Starr et al.,
2013; Starr, Porsch, Seed, & St. Geme III, 2016). Recent work has determined that the K.
kingae polysaccharide capsule and exopolysaccharide confer high-level resistance to
human serum (Muñoz et al., 2018). Elimination of both surface polysaccharides is
detrimental to the organism in the presence of human serum, resulting in increased
deposition of antibodies and complement fragments, and ultimately, complement
activation and bacterial lysis (Muñoz et al., 2018).
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Neutrophils are the most abundant leukocyte type in the blood and the predominant
infiltrating leukocyte type during acute inflammation (D. M. Walker, 2004). These cells
mobilize to clear pathogenic bacteria through various extracellular and intracellular
mechanisms and are primed and activated by a variety of inflammatory stimulants,
including conserved bacterial ligands known as pathogen associated molecular patterns
(PAMPs). PAMPS are recognized by membrane-associated Toll-like receptors (TLRs),
and subsequent TLR activation primes neutrophils and promotes phagocytosis,
degranulation, and production of reactive oxygen species (ROS).
Given the role of neutrophils in combating microbial invaders, bacteria have
evolved multiple mechanisms to evade neutrophil-mediating killing. Encapsulation by
invasive pathogens such as Streptococcus pneumoniae and Neisseria meningitidis has been
demonstrated to promote bacterial survival by inhibiting neutrophil recognition and
activation (Beiter et al., 2008; Campos et al., 2004; Hyams et al., 2010). Encapsulation has
also been demonstrated to prevent antibody recognition of surface antigens present on the
bacterial surface and to inhibit complement deposition and activation (Geoffroy et al.,
2003; Horwitz & Silverstein, 1980; Hyams et al., 2010; Peterson et al., 1978). Opsonization
by immunoglobulins and complement components augments neutrophil recognition and
enhances neutrophil antimicrobial activity, including phagocytosis of opsonized bacteria.
In this study, we found that the K. kingae polysaccharide capsule promotes
neutrophil evasion by preventing neutrophil activation, dampening ROS production, and
inhibiting initial neutrophil binding of K. kingae. Interestingly, we observed a distinctive
role for the exopolysaccharide in promoting K. kingae survival in the presence of
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neutrophil antimicrobial peptides and blocking neutrophil phagocytosis of bound bacteria.
The absence of both the polysaccharide capsule and the exopolysaccharide increased
neutrophil opsonophagocytosis of K. kingae. This study demonstrates the importance of
the K. kingae polysaccharide capsule and exopolysaccharide in neutrophil evasion,
presumably promoting hematogenous dissemination of K. kingae.

3.2 Methods
3.2.1 Bacterial strains and growth conditions
The strains used in this study are listed in Table 3. K. kingae strains were stored at
-80°C in brain heart infusion (BHI) broth with 20% glycerol. E. coli strains were stored at
-80°C in Luria-Bertani (LB) broth with 15% glycerol. K. kingae strains were grown at 37°C
with 5% CO2 on chocolate agar plates supplemented with 50 µg/ml kanamycin or 1 µg/ml
erythromycin, as appropriate. E. coli strains were grown at 37°C on LB agar or shaking at
250 rpm in LB broth supplemented with 100 µg/ml ampicillin or 50 µg/ml kanamycin, as
appropriate.

Strain
Kingella kingae

Table 3: Strains and plasmids used in this study
Description

KK01

Nonspreading/noncorroding derivative of
269-492

KK01 csaA

KK01 with csaA deletion

KK01 pam

KK01 with pamABCDE deletion
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Reference
(Kehl-Fie &
St. Geme III,
2007)
(Starr, Porsch,
Seed, & St.
Geme III,
2016)
(Starr et al.,
2013)

KK01 csaApam
KK01 rtx
KK01 csaArtx
KK01 pamrtx
KK01 csaApamrtx
E. coli
DH5a

KK01 with csaA deletion and pamABCDE
deletion
KK01 with rtxACDB deletion
KK01 with csaA deletion and rtxACDB
deletion
KK01 with pam deletion and rtxACDB
deletion
KK01 with csaA deletion, pam deletion,
and rtxACDB deletion
-

E. coli F φ80dlacZ∆M15 ∆(lacZYAargF)U169 deoR recA1 endA1 hsdR17(rK

(Muñoz et al.,
2018)
This study
This study
This study
This study

(Sambrook et
al., 1989)

+

mK ) phoA supE441 thi-1 gyrA96 relA1
Plasmid
E. coli
pUC19rtxACDB::kan

Description
pUC19 with aphA3 kanamycin cassette
flanked by surrounding 5’ and 3’ regions
of the rtxACDB locus

Reference
This study

3.2.2 Strain construction
Strains KK01 csaA, KK01 pam, and KK01 csaApam were generated as previously
described (Muñoz et al., 2018; Starr et al., 2013; Starr, Porsch, Seed, & St. Geme III, 2016).
Briefly, plasmid-based gene disruption constructs were created in E. coli, linearized, and
introduced into K. kingae using natural transformation. Transformants were recovered by
selectively plating on chocolate agar plates with the appropriate antibiotic. Gene
disruptions were confirmed by PCR.
To generate pUC19rtxBDCA::kan, DNA fragments of the homologous
recombination targeting sequence corresponding to the ~1 kb upstream of rtxB and the ~1
kb downstream of rtxA were PCR amplified from strain KK01 genomic DNA using primers
rtx 5’ For/ rtx 5’ Rev and rtx 3’ For/ rtx 3’ Rev, respectively, and were cloned into pUC19
(Table 4). A kanamycin resistance cassette was then ligated into the BamHI site located
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between the cloned upstream and downstream homologous recombination targeting
sequences. The plasmid was linearized with NdeI and was transformed into strain KK01,
KK01 csaA, KK01 pam, and KK01 csaApam via natural transformation. Transformants
were recovered on chocolate agar plates containing 50 µg/ml kanamycin. Correct insertion
of the gene disruption construct was confirmed via PCR and sequencing of the deletion
site.

Primer
rtx 5’ For

Table 4: Primers used in this study
Sequence (5’ -3’)
GCAGGAATTCAATCTTGCGAATTTGGTGTG

Reference
This study

rtx 5’ Rev

GCACGGATCCTCGGGCTGATAAATGCCGAC

This study

rtx 3’ For
rtx 3’ Rev

GCACGGATCCAGCTGAACAACGATTCAATG
GCAGAAGCTTAGAGCTGCGCGTAACCTATG

This study
This study

3.2.3 Neutrophil purification
Human neutrophils were obtained from healthy adult donors using approved IRB
protocol IRB 16-012812 at the Children’s Hospital of Philadelphia. Whole blood was
collected in a Vacutainer K2E 18mg (BD, Franklin Lakes, NJ). Neutrophils were isolated
as previously described (Ermert, Zychlinsky, & Urban, 2009). Briefly, neutrophils were
purified using 3% dextran sedimentation for 30 min at room temperature (RT) to separate
red blood cells (RBCs) from the leukocyte-rich supernatant. The supernatant was
transferred into a new conical tube, and 1 volume of Hypaque Ficoll (Sigma-Aldrich, St.
Louis, MO) was added underneath the supernatant. The sample was centrifuged at 300 g
for 30 min to pellet the neutrophils. The remaining RBCs were subjected to hypotonic lysis
with cold double-distilled water, and the isotonicity was restored by the addition of RPMI67

HEPES (RPMI (Lonza, Walkersville, MD) without phenol red, substituted with 10 mM
HEPES (Sigma-Aldrich, St. Louis, MO)). Neutrophils were pelleted and resuspended in
RPMI-HEPES for experimental use.

3.2.4 Neutrophil killing assay
Killing assays with neutrophils were performed as previously described (Ermert et
al., 2009). Briefly, neutrophils were diluted to 2.0 x 10 cells/ml, and 500 µl was seeded
6

onto 24-well plates in RPMI-HEPES with 1% human serum albumin (HSA) (Alfa Aesar,
Ward Hill, MA) or 1% normal human serum (NHS) (Immucor, Norcross, GA). Bacteria
were resuspended to an OD of ~0.8 in phosphate-buffered saline (PBS) and added at both
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a high and low multiplicity of infection (MOI), 10:1 or 1:10, respectively, and centrifuged
at 1000 rpm for 2 min. Samples were incubated for various time points at 37°C with 5%
CO . After incubation, the supernatant was removed and placed in 1.5-mL reaction tubes.
2

Neutrophils were lysed using cold double-distilled water, wells were scraped, and the
lysate was added to the corresponding collected supernatants. Serial dilutions of the
inoculum and reaction samples were plated on chocolate agar plates and incubated
overnight at 37°C with 5% CO to determine CFU counts (limit of detection for plating: 20
2

CFU). To perform inhibition assays, neutrophils were incubated with 10 µg/ml
cytochalasin D (Life Technologies Corp., Frederick, MD), 10 mM N-acetylcysteine
(MilliporeSigma, Burlington, MA), 4 µM diphenyleneiodonium (XXX), or 1x protease
inhibitor cocktail (Roche Diagnostics, Indianapolis, IN) for 30 min prior to infection with
bacteria.
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3.2.5 Oxidative burst studies
To detect intracellular and extracellular reactive oxidative species (ROS) generated
by neutrophils, the neutrophils were diluted to 2.0 x 10 cells/ml and seeded onto a white
5

tissue culture-treated 96-well microtiter plate with 1% HSA or 1% NHS as previously
described (Engels, Endert, Kamps, & Van Boven, 1985; Mishra et al., 2012). The bacteria
were resuspended to an OD of ~0.8 in phosphate-buffered saline (PBS) and added at a
600

MOI of 10:1 to wells in the presence of 50 µM luminol. The microtiter plate was
centrifuged at 100 g for 2 min and the relative amount of ROS generated by neutrophils
was detected at 5 min intervals over 60 min by luminescence. Phorbol 12-myristate 13acetate (PMA) (Alfa Aesar, Wardhill, MA) at a concentration of 40 ng/ml was used as a
positive control for the generation of ROS by neutrophils.

3.2.6 Microscopy
Bacterial ingestion by neutrophils
To detect binding and phagocytosis of bacteria by neutrophils, neutrophils were
diluted to 2.0 x 10 cells/ml and seeded onto tissue culture-treated glass coverslips with 1%
6

HSA or 1% NHS (Mishra et al., 2012; Tuominen-Gustafsson, Penttinen, Hytönen, &
Viljanen, 2006). Bacteria were resuspended to an OD of ~0.8 in PBS, stained with 5 µg/ml
600

CFSE (Tonbo Biosciences, San Diego, CA) for 20 min at 37°C, and washed twice with
PBS. CFSE-stained bacteria were added at an MOI of 10:1 and centrifuged at 1000 rpm
for 2 min. Samples were incubated for 30 min at 37°C with 5% CO2. Cells were washed
twice with PBS to remove non-adherent bacteria and were fixed at RT for 15 min using
4% paraformaldehyde in PBS. Samples were incubated with anti-K. kingae antibody
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(1:500) overnight at 4°C. The anti-K. kingae antibody was generated against an acetone
powder of K. kingae strain KK01 whole bacteria. Cells were washed twice with PBS and
incubated with a 1:500 dilution of goat anti-guinea pig IgG DyLight 649-conjugated
antibody (Rockland, Limerick, PA).
Visualization of bacteria–neutrophil association was performed by microscopy
using a Nikon Eclipse Ni-E (Nikon Instruments Inc., Melville, NY) with either a 20x
objective or 60x oil objective. For quantification, 100 neutrophils per n=1 were chosen at
random for analysis; the cell-associated versus extracellular bacteria were counted by a
blinded reader.

3.2.7 Antibacterial peptide bactericidal assays
K. kingae strains were grown on chocolate agar plates and then resuspended in PBS.
Samples were diluted in PBS to obtain a final inoculum of approximately 4.0 x 103 CFU/0.1
ml. The respective inocula were mixed with polymyxin B (Alfa Aesar, Ward Hill, MA),
HNP 1-3 (MilliporeSigma, Burlington, MA), or LL-37 (Bachem, Torrance, CA) at various
concentrations and incubated at 37°C with 5% CO2 for 30 min. After incubation, 9 mM of
MgCl2 was added to the reaction prior to plating. Serial dilutions of the inoculum and
reaction samples were plated on chocolate agar plates and incubated overnight at 37°C with
5% CO2 to determine the CFU counts (limit of detection for plating, 20 CFU).

3.2.8 Ethics statement
Blood samples for neutrophil isolation were obtained from healthy adult donors
that provided oral informed consent under approved Children’s Hospital of Philadelphia
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Institutional Review Board (CHOP IRB) protocol IRB 16-012812 in compliance with all
institutional and federal guidelines. Due to the nature of the study, the CHOP IRB indicated
that oral consent was appropriate and approved its use. Oral informed consent from each
study participant was recorded on a copy of the Verbal Consent Form, which were
maintained in the study records.

3.2.9 Statistical analysis
Statistical analyses were performed with GraphPad Prism (version 7.0a) software
for Mac (GraphPad Software, San Diego, CA), where a P value of <0.05 was considered
statistically significant. The specific statistical tests used for each experiment are specified
in the figure legends.

3.3 Results
3.3.1 The K. kingae capsule and exopolysaccharide prevent neutrophilmediated killing of K. kingae.
In previous work we demonstrated that the polysaccharide capsule and
exopolysaccharide expressed by K. kingae protect the organism from complementmediated lysis and promote virulence in an infant rat model of infection (Muñoz et al.,
2018; Starr et al., 2013; Starr, Porsch, Seed, & St. Geme III, 2016). To further characterize
the role of these surface polysaccharides in innate immune evasion, we performed
neutrophil-killing assays using K. kingae strain KK01, the capsule-deficient mutant KK01
csaA (Starr, Porsch, Seed, & St. Geme III, 2016), the exopolysaccharide-deficient mutant
KK01 pam (Starr et al., 2013), and the capsule-deficient and exopolysaccharide-deficient
mutant KK01 csaApam (Muñoz et al., 2018). Using an MOI of 0.1 or 10, the K. kingae
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strains were incubated with or without purified human neutrophils for 1 hr in the presence
of 1% normal human serum (NHS) as a source of serum opsonins or 1% human serum
albumin (HSA) as a control. To assess extracellular and intracellular survival of K. kingae
in the presence of neutrophils, supernatant and neutrophil lysates were diluted and plated
to determine colony forming units (CFU). Survival percentage was calculated by dividing
the recovered CFU by the inoculated CFU.

Figure 11: Elimination of the K. kingae capsule results in K. kingae killing by
neutrophils.
K. kingae strains KK01 (A), KK01 csaA (B), KK01 pam (C), and KK01 csaApam (D)
were incubated with human neutrophils at an MOI of 10 or 0.1 for 1 hr in the presence
of 1% HSA or 1% NHS. Black bars indicate survival in the absence of neutrophils,
and white bars represent survival in the presence of neutrophils. Survival was
determined by dividing the recovered CFU by the inoculum CFU. Statistical
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significance was determined using two-way ANOVA and the Tukey post hoc test. *, P
< 0.05; **, P < 0.01; ****, P < 0.0001.
Elimination of the capsule, the exopolysaccharide, or both the capsule and the
exopolysaccharide resulted in no growth defects on solid agar (Muñoz et al., 2018) and had
no effect on survival in the absence of neutrophils or 1% NHS alone (Fig. 11, black bars
and Fig. 12). Survival of strains KK01 and KK01 pam was only slightly affected at an MOI
of 0.1 in the presence of neutrophils with 1% NHS (Fig. 11A, C). Survival of strain KK01
csaA was reduced in the presence of neutrophils with 1% NHS at both MOIs and in the
presence of neutrophils with 1% HSA at an MOI of 0.1 with ~60% survival (Fig. 11B).
Interestingly, survival of strain KK01 csaApam was markedly reduced in the presence of
neutrophils at both MOIs (Fig. 11D). In contrast to the other strains tested, strain KK01
csaApam was more susceptible to neutrophil-mediated killing when opsonins were present,
with ~30% survival with opsonins compared to ~50% survival without opsonins (Fig.
11D). These results establish that the capsule is critical for K. kingae neutrophil evasion
and that the exopolysaccharide plays a conditional protective role when opsonins are
present and the capsule is absent.
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Figure 12: Survival of K. kingae in the presence of 1% normal human serum.
K. kingae strains KK01, KK01 csaA, KK01 pam, and KK01 csaApam were incubated
with 1% normal human serum at an MOI equivalent of 0.1 (white bars) or 10 (black
bars) for 1 hr in the absence of neutrophils. Survival was determined by dividing the
recovered CFU by the inoculum CFU.

3.3.2 The K. kingae capsule inhibits the neutrophil oxidative burst
response.
The oxidative burst response generated by human neutrophils is a critical innate
immune defense mechanism against bacterial pathogens. K. kingae expresses a cytotoxin
called RtxA that is capable of rapidly killing a variety of human cell types, including
leukocytes (Chang et al., 2014; Kehl-Fie & St. Geme III, 2007; Maldonado et al., 2011).
In vitro, strains KK01 and KK01 rtx (a mutant with the rtx locus deleted) demonstrate
similar survival in the presence of neutrophils at an MOI of 10 (Fig. 13). However, to
eliminate the influence of the RtxA toxin as a confounding variable on neutrophil activation
and ROS production in the presence of K. kingae, we deleted the rtx locus in strains KK01,
KK01 csaA, KK01 pam, and KK01 csaApam. To determine the oxidative burst response,
we incubated the K. kingae rtx mutant strains at an MOI of 10 with human neutrophils and
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either 1% HSA or 1% NHS in the presence of luminol (Fig. 14A-C). Based on
measurement of chemiluminescence (relative light units, RLU) at 5 min intervals over a 1
hr incubation period, incubation of strains KK01 rtx and KK01 pamrtx with neutrophils
resulted in a moderate neutrophil response when compared to the uninfected control (Fig.
14A, B). In contrast, incubation of strains KK01 csaArtx and KK01 csaApamrtx resulted
in a rapid and robust neutrophil response, peaking at the 25 min time point (Fig. 14A, B).

Figure 13: Elimination of RtxA toxin has no effect on K. kingae survival in the
presence of neutrophils.
K. kingae strains KK01 (A), KK01 rtx (A), KK01 csaA (B), KK01 csaArtx (B), KK01
pam (C), KK01 pamrtx (C), KK01 csaApam (D), and KK01 csaApamrtx (D) were
incubated with human neutrophils at an MOI of 10 for 1 hr in the presence of 1%
HSA (white bars) or 1% NHS (black bars). Survival was determined by dividing the
recovered CFU by the inoculum CFU.
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Focusing on the 25 min time point, the neutrophil response was compared across
the KK01 rtx mutant strains in either 1% HSA or 1% NHS. In both 1% HSA and 1% NHS,
we observed a statistically significant increase in the neutrophil response to strains KK01
csaArtx and KK01 csaApamrtx when compared to strain KK01 rtx (Fig. 14C). Comparison
of strains KK01 rtx and KK01 pamrtx in 1% HSA or 1% NHS revealed no statistically
significant difference in neutrophil response (Fig. 14C). Similarly, comparison of strains
KK01 csaArtx and KK01 csaApamrtx in 1% HSA revealed no statistically significant
difference in neutrophil response (Fig. 14C). In contrast, there was a statistically significant
increase in neutrophil response to strain KK01 csaApamrtx compared to strain KK01
csaArtx in 1% NHS (Fig. 14C). These data suggest that K. kingae encapsulation prevents
neutrophil activation and ROS production and release. Moreover, the neutrophil response
is most robust when both surface polysaccharides are absent and opsonins are present.
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Figure 14: The absence of the K. kingae capsule results in an enhanced neutrophil
oxidative burst response.
K. kingae rtx mutant strains were incubated with human neutrophils at an MOI of 10
in the presence of 1% HSA (A) or 1% NHS (B). Chemiluminescence was measured at
5-min intervals for 60 min for kinetic analysis (A, B) or at the 25-min time point (C).
Statistical significance was determined using two-way ANOVA and the Tukey post
hoc test. RLU, relative light unit; n.s., not significant; **, P < 0.01; ****, P < 0.0001.

3.3.3 Neutrophil-mediated killing of capsule-deficient K. kingae is
dependent on phagocytosis and ROS production.
Neutrophils are recruited early during infection and can eliminate pathogens
through a variety of mechanisms, including phagocytosis and the oxidative burst (Nathan,
2006). To determine whether phagocytosis and/or ROS production facilitates killing of
non-encapsulated K. kingae strains, we performed neutrophil-killing assays in the presence
of cytochalasin D (Cyto D), the antioxidant N-acetylcysteine (NAC), or the NADPH
oxidase inhibitor, diphenyleneiodonium (DPI). Using an MOI of 0.1, strains KK01 csaA
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and KK01 csaApam were incubated with Cyto D, NAC, or DPI pre-treated human
neutrophils for 30 min. Pretreatment of neutrophils with Cyto D restored survival of strains
KK01 csaA and KK01 csaApam in the presence of neutrophils (Fig. 15A, B). Pretreatment
of neutrophils with NAC led to a roughly two-fold increase in the percent survival for
strains KK01 csaA and KK01 csaApam in 1% HSA and 1% NHS, but did not completely
restore survival to the level observed with vehicle-only pretreated neutrophils (Fig. 15C,
D). Similarly, pretreatment of neutrophils with DPI led to a significant increase in the
percent survival for strain KK01 csaA in 1% HSA (Fig. 15E). Pretreatment of neutrophils
with DPI led to a roughly two-fold increase in the percent survival for strain KK01
csaApam but did not completely restore survival (Fig. 15F). These data suggest that
phagocytosis and ROS are key mechanisms contributing to neutrophil-mediated killing of
non-encapsulated K. kingae.
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Figure 15: Inhibition of neutrophil phagocytosis and ROS production enhances
survival of non-encapsulated K. kingae.
K. kingae strains KK01 csaA and KK01 csaApam were incubated with human
neutrophils at an MOI of 0.1 for 30 min. Neutrophils were preincubated with 10 µg/ml
cytochalasin D, Cyto D (A, B), 10 mM N-acetylcysteine, NAC (C, D), or 4 µM
diphenyleneiodonium (E, F) in the presence of 1% HSA or 1% NHS. Black bars
indicate survival in the absence of neutrophils, white bars represent survival in the
presence of neutrophils, and gray bars represent survival in the presence of
neutrophils pretreated with Cyto D, NAC, or DPI. Survival was determined by
calculating the recovered CFU by the inoculum CFU. Statistical significance was
determined using two-way ANOVA and the Tukey post hoc test. n.s., not significant,
*, P < 0.05; ***, P < 0.001; ****, P < 0.0001.

3.3.4 The K. kingae exopolysaccharide protects against neutrophil
antimicrobial peptides.
Neutrophil granules are cytoplasmic vesicles that can fuse with phagosomes or the
plasma membrane to release degradative enzymes (e.g. myeloperoxidase, elastase, and
cathepsin G), antimicrobial peptides (e.g. defensins and the cathelicidin LL37), and
reactive radicals to kill intracellular and extracellular microorganisms (Nathan, 2006). To
determine whether proteases released during degranulation facilitate killing of K. kingae,
we performed neutrophil-killing assays in the presence of a protease inhibitor cocktail (PI).
Using an MOI of 0.1, strains KK01 csaA and KK01 csaApam were incubated with PIpretreated human neutrophils for 30 min. Pretreatment of neutrophils with PI had no
statistically significant effect on levels of survival for strains KK01 csaA and KK01
csaApam (Fig. 16A, B). To determine the sensitivity of K. kingae in the presence of
antimicrobial peptides, we performed bactericidal assays with a bacterial peptide,
polymyxin B, and human peptides, LL-37 and HNP 1-3, at a range of physiologic
concentrations. Survival of strain KK01 csaA compared to strain KK01 was not affected
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in the presence of polymyxin B and was slightly decreased in the presence of LL-37 (Fig.
16C, D). Interestingly, survival of strain KK01 pam compared to strain KK01 was
significantly decreased in the presence of polymyxin B or LL-37 (Fig. 16C, D). Strain
KK01 csaApam was most sensitive in the presence of polymyxin B and LL-37 compared
to strain KK01 (Fig. 16C, D). We observed no change in survival of the mutant strains
compared to strain KK01 in the presence of HNP 1-3 (Fig. 16E). These results establish
that the exopolysaccharide is critical for survival of K. kingae in the presence of
antimicrobial peptides and demonstrate a moderate role for the capsule.
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Figure 16: The surface polysaccharides protect K. kingae against antimicrobial
peptides.
K. kingae strains KK01 csaA and KK01 csaApam were incubated with human
neutrophils preincubated with a protease inhibitor cocktail (PI) at an MOI of 0.1 for
30 min in the presence of 1% HSA or 1% NHS (A, B). Black bars indicate survival in
the absence of neutrophils, white bars represent survival in the presence of
neutrophils, and gray bars represent survival in the presence of neutrophils
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pretreated with PI. K. kingae strains and E. coli strain DH5a were incubated with
various concentrations of antimicrobial peptides, polymyxin B (C), cathelicidin LL37 (D), or HNP1-3 (E) for 30 min. Survival was determined by calculating the
recovered CFU by the inoculum CFU.

3.3.5 The K. kingae surface polysaccharides inhibit neutrophil binding
and phagocytosis of bacteria.
To further delineate the mechanism of neutrophil-mediated killing of K. kingae
strains, we performed immunofluorescence microscopy, examining the number of K.
kingae associated with neutrophils and the nature of association. K. kingae rtx mutant
strains were used to prevent cell lifting during infection. K. kingae strains were stained
with carboxyfluorescein succinimidyl ester (CFSE) prior to infection and were incubated
at an MOI of 10 with human neutrophils for 30 min or 60 min in presence of 1% HSA or
1% NHS. The wells were washed vigorously to remove any unassociated bacteria, and the
samples were incubated with an anti-K. kingae whole organism guinea pig antiserum to
detect extracellular bacteria associated with the neutrophils. For the 30 min time point, the
total number of associated bacteria (intracellular and extracellular) was 2.8-fold higher for
strain KK01 csaArtx compared to strain KK01 rtx in 1% HSA and 1.6-fold higher for strain
KK01 csaArtx compared to strain KK01 rtx in 1% NHS (Fig. 17A, Table 5). The total
number of associated bacteria was 4.0-fold higher for strain KK01 csaApamrtx compared
to strain KK01 rtx in 1% HSA and 3.1-fold higher for strain KK01 csaApamrtx compared
to strain KK01 rtx in 1% NHS (Fig. 17A, Table 5). While we observed an increase in total
bacterial association with strain KK01 csaArtx compared to strain KK01 rtx, there was no
significant difference between the number of intracellular bacteria (Fig. 17B, C, Table 5).
In contrast, we observed a significant increase in the number of intracellular KK01
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csaApamrtx compared to strains KK01 rtx, KK01 csaArtx, and KK01 pamrtx in 1% HSA
and 1% NHS (Fig. 17B-E). We also observed a statistically significant increase in the total
number of associated bacteria for strain KK01 csaApamrtx in 1% NHS compared to 1%
HSA (Table 5).
At the 60 min time point, we observed an increase in total number of associated
bacteria for strains KK01 rtx, KK01 csaArtx, and KK01 pamrtx; however, the number of
intracellular bacteria remained similar across the 30 min and 60 min time points (Table 5,
Fig. 17B-D, F-H). We observed a slight increase in total number of associated bacteria for
strain KK01 csaApamrtx at 60 min (Table 5). Comparing the 60 min time point to the 30
min time point, there was a significant decrease in the number of extracellular bacteria and
a slight increase in the number of intracellular bacteria for strain KK01 csaApamrtx (Fig.
17E, I).
Taken together, these results demonstrate that the absence of capsule results in
increased bacterial association with neutrophils and that only the elimination of both the
capsule and the exopolysaccharide results in a significant increase of K. kingae
phagocytosis by neutrophils, regardless of opsonin deposition.
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Figure 17: The presence of the K. kingae surface polysaccharides results in reduced
neutrophil association and phagocytosis of K. kingae.
Immunofluorescence images (A) and quantitative analysis (B-I) of K. kingae rtx
mutant strains incubated with human neutrophils at an MOI of 10 for 30 min (A-I)
or 60 min (B-I) in the presence of 1% HSA or 1% NHS. K. kingae strains were stained
with CFSE (green) prior to infection. Neutrophils were fixed and incubated with a
guinea pig anti-K. kingae antiserum and subsequently with anti-guinea pig AF-649 to
detect extracellular bacteria (red). DAPI was used to stain the nuclei of the
neutrophils (blue). Images were acquired using a 20x objective. Arrows indicate
extracellular bacteria, and arrowheads indicate intracellular bacteria. Scale bar is
equal to 5 µm. Graphs depict the total number of CFSE+/AF649- (intracellular, B-E)
events and the total number of CFSE+/AF649+ (extracellular, F-I) for strains KK01
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rtx (B, F), KK01 csaArtx (C, G), KK01 pamrtx (D, H), and KK01 csaApamrtx (E, I).
The data represents total number of CFSE+ events per 100 neutrophils chosen
randomly per n=1. Abbreviations: H, HSA; N, NHS; KK, K. kingae; ecKK,
extracellular K. kingae.
Table 5: Total number of CFSE- bacteria associated with human neutrophils
Strain

1% HSA
30 min
60 min

1% NHS
30 min
60 min

KK01 rtx

(21±8.2)

(59±9.2)

(35±7.0)

(43±13.1)

KK01 csaArtx

(59 ± 9.5)

(79±7.1)

(56 ±3.6)

(79±2.3)

KK01 pamrtx

(36 ± 5.5)

(58±5.9)

(38 ± 3.2)

(45±11.7)

KK01
csaApamrtx

(85 ± 9.0)

(96±9.0)

(109 ± 7.8)

(95±9.5)

*The number (mean ± SD) of associated bacteria is indicated in parentheses. The data
represents total number of CFSE+ events per 100 neutrophils chosen randomly per
n=1.

3.4 Discussion
The pathogenesis of K. kingae disease involves bacterial invasion of the
bloodstream, evasion of complement- and neutrophil-mediated killing, and dissemination
to distant sites (Amit et al., 2013; Bidet et al., 2013; Kehl-Fie & St. Geme III, 2007;
Yagupsky et al., 2006, 2009). The K. kingae surface polysaccharides have proven to be
critical for complement evasion, and expression of both the capsule and the
exopolysaccharide is essential for full virulence in the infant rat model of infection (Muñoz
et al., 2018). In this study, we observed that in the absence of the polysaccharide capsule,
K. kingae was sensitive to neutrophil-mediated killing. This phenotype was enhanced when
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the exopolysaccharide was also absent. Further analysis demonstrated that the
polysaccharide capsule prevented neutrophil ROS production and interfered with
neutrophil binding of K. kingae but had a limited effect on resistance to neutrophil
antimicrobial peptides and no direct effect on phagocytosis. In contrast, the
exopolysaccharide conferred resistance to neutrophil antimicrobial peptides and blocked
neutrophil phagocytosis but had a limited effect on neutrophil binding of K. kingae.
Overall, we have established a novel interplay between the K. kingae polysaccharide
capsule and exopolysaccharide, which have complementary but distinct roles in mediating
resistance to human neutrophils.
Polysaccharide capsules expressed by invasive pathogens such as N. meningitidis
and S. pneumoniae promote bacterial survival during infection by interfering with
neutrophil recognition, activation, and phagocytosis (Hyams et al., 2010; Spinosa et al.,
2007; Wartha et al., 2007). In this study, we demonstrated that the presence of the K. kingae
polysaccharide capsule significantly reduced the oxidative burst response by neutrophils.
Many encapsulated pathogens prevent ROS production by inhibiting serum opsonization
(Horwitz & Silverstein, 1980; Hyams et al., 2010; Peterson et al., 1978). In the case of K.
kingae, elimination of the polysaccharide capsule increased ROS production regardless of
the presence of human serum. Interestingly, only elimination of both the polysaccharide
capsule and the exopolysaccharide led to a significant increase in ROS production when
opsonins were present. These data are consistent with our previous study demonstrating
that the presence of either the polysaccharide capsule or the exopolysaccharide was
sufficient to prevent opsonization of K. kingae (Muñoz et al., 2018). Our results suggest
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that encapsulation prevents ROS production through mechanisms beyond hindering
opsonin deposition. We hypothesize that when the K. kingae polysaccharide capsule is
absent, increased neutrophil recognition of bacterial lipopolysaccharide (LPS) prompts
TLR4 activation. TLR4 is activated by LPS and upon activation recruits the NADPHoxidase complex, Nox4, leading to the generation of ROS (Kaisho & Akira, 2006; Ngkelo,
Meja, Yeadon, Adcock, & Kirkham, 2012; Park et al., 2004; Qureshi et al., 1999). Future
studies will assess the stimulatory potential of K. kingae LPS.
Aside from preventing ROS production, the K. kingae polysaccharide capsule
decreased the total number of neutrophil-associated bacteria. It is well-documented that
bacterial polysaccharide capsules prevent neutrophil association by blocking opsonization
(Horwitz & Silverstein, 1980; Hyams et al., 2010; Peterson et al., 1978). Interestingly, in
our studies neutrophil binding of K. kingae occurred regardless of opsonization, similar to
ROS production. Studies have shown nonopsonic neutrophil interactions by N.
gonorrhoeae and H. pylori through the expression of adhesins on the bacterial surface
(Craig, Lackie, Parton, & Freer, 1988; Fischer & Rest, 1988; Rautelin, Blomberg, Jårnerot,
& Danielsson, 1994; Rest & Frangipane, 1992). In our previous work, we established that
the K. kingae polysaccharide capsule can interfere with adherence to epithelial cells
(Porsch et al., 2012). In the absence of type IV pili, the polysaccharide capsule masks the
trimeric autotransporter, Knh, and deletion of the capsule locus restores Knh-mediated
adherence to wild-type levels (Porsch et al., 2012). Neutrophil-killing assays have not been
performed using Knh-deficient or pili-deficient K. kingae strains to determine whether
association with neutrophils is affected by these adhesins.
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It is noteworthy that despite an increase in the total number of bound bacteria, the
elimination of capsule did not increase phagocytosis regardless of opsonization. This
observation suggests that the K. kingae exopolysaccharide inhibits or delays neutrophil
phagocytosis. Exopolysaccharide secretion in other bacterial pathogens is commonly
associated with biofilm formation, promoting survival in the host by inhibiting
opsonization and phagocytosis (Jesaitis et al., 2003; Jones & Wozniak, 2017; Yamanaka
et al., 2011). Based on previous studies, we presume that the K. kingae exopolysaccharide
remains loosely tethered to the K. kingae cell surface, at least in part (Muñoz et al., 2018;
Starr et al., 2013). Surface analysis using scanning electron microscopy may be beneficial
for identifying structural or physical changes in the K. kingae cell surface that alter
interactions with human neutrophils to inhibit or reduce neutrophil phagocytosis.
Alternatively, the presence of the exopolysaccharide on the K. kingae bacterial surface may
mask surface antigens that are recognized by neutrophil receptors and trigger phagocytosis.
Cationic antimicrobial peptides function through electrostatic interactions with
anionic bacterial surfaces (Brogden, 2005; Hancock & Chapple, 1999; Nicolas & Mor,
1995; Martti Vaara, 1992). While bacterial polysaccharide capsules vary in their polymer
composition, most capsules are anionic and have been shown to bind antimicrobial peptides
to prevent or reduce undesirable interactions with the bacterial surface (Campos et al.,
2004; Spinosa et al., 2007; Wartha et al., 2007). Surprisingly, there are cases where the
lack or loss of the polysaccharide capsule increases resistance to antimicrobial peptides,
with examples including S. pneumoniae and Campylobacter jejuni (Beiter et al., 2008;
Zilbauer et al., 2005). Given that the K. kingae polysaccharide capsule blocks antibody
89

recognition of surface antigens (Muñoz et al., 2018), we hypothesized that the capsule
would be necessary for complete protection against antimicrobial peptides. Interestingly,
loss of the polysaccharide capsule had no effect on K. kingae survival in the presence of
polymyxin B and only slightly affected survival in the presence of cathelicidin LL-37. In
contrast, elimination of the exopolysaccharide resulted in a marked decrease in K. kingae
survival in the presence of increasing concentrations of either polymyxin B or LL-37 when
compared to the wild-type strain, suggesting that the exopolysaccharide is essential for
antimicrobial peptide resistance. Llobet et al. demonstrated that free capsular material shed
or purified from K. pneumoniae, S. pneumoniae, or Pseudomonas aeruginosa acted as a
decoy by sequestering and neutralizing polymyxin B and HNP-1 (Llobet, Tomás, &
Bengoechea, 2008). The secretion and release of the high molecular weight
exopolysaccharide by K. kingae may provide a physical barrier and also actively scavenge
antimicrobial peptides to protect K. kingae more efficiently than the polysaccharide
capsule. Similar to K. kingae survival in the presence of neutrophils, elimination of both
the capsule and the exopolysaccharide led to the most sensitive phenotype in assays with
antimicrobial peptides, suggesting that the capsule plays a minor role in protection when
the exopolysaccharide is absent.
Given the robust oxidative burst response and phagocytic activities of neutrophils
in assays with surface polysaccharide-deficient K. kingae, pretreatment of neutrophils with
ROS inhibitors, DPI and NAC, or an actin polymerase inhibitor, Cyto D, restored survival
of K. kingae mutants to wild-type levels. Together, our data suggest that killing of the
capsule-deficient K. kingae strains is predominately due to ROS production, whereas the
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enhanced killing of the capsule-deficient and exopolysaccharide-deficient K. kingae is
meditated through both ROS production and phagocytosis. Furthermore, degranulation and
release

of

antimicrobial

peptides

by

neutrophils

may

augment

killing

of

exopolysaccharide-deficient K. kingae.
In our earlier work, we observed redundancy of the the K. kingae polysaccharide
capsule and exopolysaccharide in preventing antibody and complement deposition on the
bacterial surface (Muñoz et al., 2018). In this study, we observed largely distinct but
interdependent roles for the polysaccharide capsule and the exopolysaccharide in
protecting K. kingae from neutrophil-mediated killing and antimicrobial peptides. This
study demonstrates the protective functions of the K. kingae polysaccharide capsule and
exopolysaccharide against human neutrophils and highlights the robust and multifaceted
mechanisms employed by K. kingae to evade innate immunity.
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4. Diversity and genetic characterization of the Kingella kingae
exopolysaccharide among clinical isolates
4.1 Introduction
Kingella kingae is a fastidious gram-negative oropharyngeal commensal bacterium
in humans and has been described as an emerging pediatric pathogen (Yagupsky et al.,
2009, 2011). In previous work, we described the production of two surface
polysaccharides, the polysaccharide capsule and the exopolysaccharide, by the K. kingae
strain KK01 (a septic arthritis clinical isolate). Genetic and structural analyses of the
capsule synthesis loci from a diverse collection of K. kingae clinical isolates established
the presence of four distinct capsule types (types a, b, c, and d) (Starr, Porsch, Seed, Heiss,
et al., 2016). Interestingly, capsule types a and b were predominant among invasive disease
isolates suggesting an association between capsule type and clinical presentation (Porsch
et al., 2017; Starr, Porsch, Seed, Heiss, et al., 2016). While the genetic determinants and
diversity of the K. kingae polysaccharide capsule have been extensively studied, little is
known about the exopolysaccharide synthesis locus, pamABCDE, and diversity among
carrier and invasive clinical isolates.
Exopolysaccharide function depends on the polymer structure and composition and
in other bacterial species has been studied primarily as a major contributor to the formation
and dispersal of biofilms (Cerning, 1991; De Vuyst & Degeest, 1999; Flemming et al.,
2007; Nwodo et al., 2012). Thus far, two galactan homopolymer exopolysaccharide
structures with distinct linkages have been described in K. kingae: à5)-β-Galf-(1à and
à3)-β-Galf-(1à5)-β-Galf-(1à (Bendaoud et al., 2011; Starr et al., 2013), which we refer
to as the type 1 and type 2 exopolysaccharide, respectively. Based on previous studies of
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K. kingae strain KK01, the type 1 exopolysaccharide by prevents opsonin deposition and
complement activation, protecting the organism from human serum (Muñoz et al., 2018).
In studies of K. kingae strain PYKK181, the type 2 exopolysaccharide has been
demonstrated to contribute to biofilm dispersal (Bendaoud et al., 2011). The ability of the
K. kingae exopolysaccharides to inhibit biofilm formation and promote serum resistance
may benefit K. kingae during colonization and invasive disease. Further analysis of the
biosynthesis genes and/or machinery will provide a better foundation to determine the
presence and diversity of exopolysaccharides in K. kingae clinical isolates. Interestingly,
the exopolysaccharide pam loci present in strains KK01 and PYKK181 are highly
homologous.
In this study, we describe the genetic composition of the pam locus and found two
distinct alleles that correlate with the exopolysaccharide types. Furthermore, using PCRtyping, we examine the diversity of the exopolysaccharide among carrier and invasive
clinical isolates and established that over 99% of all isolates express the type 1
exopolysaccharide. Both the type 1 and type 2 exopolysaccharides promote serum
resistance in K. kingae isolates. Notably, the lack of diversity of the exopolysaccharide
among isolates makes the exopolysaccharide a preferential target for polysaccharideconjugate vaccines.

4.2 Methods
4.2.1 Bacterial strains and growth conditions
The strains used in this study are listed in Table 6. K. kingae strains were stored at
-80°C in brain heart infusion (BHI) broth with 20% glycerol. E. coli strains were stored at
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-80°C in Luria-Bertani (LB) broth with 15% glycerol. K. kingae strains were grown at 37°C
with 5% CO2 on chocolate agar plates supplemented with 50 µg/ml kanamycin or 1 µg/ml
erythromycin, as appropriate. E. coli strains were grown at 37°C on LB agar or shaking at
250 rpm in LB broth supplemented with 100 µg/ml ampicillin or 50 µg/ml kanamycin, as
appropriate.

4.2.2 Strain construction
Gene disruptions were introduced into K. kingae by natural transformation (KehlFie et al., 2008). Following recovery, transformants were plated on selective medium and
correct insertion of the gene disruption construct was confirmed via PCR and sequencing
of the insertion site. All of the plasmids used in this study are listed in Table 6, and the
sequences of all of the primers used are listed in Table 7.
The strains KK01 csaA, KK01 pam, and KK01csaApam were generated as
previously described (Muñoz et al., 2018; Starr et al., 2013; Starr, Porsch, Seed, & St.
Geme III, 2016). To generate mutants with deletion of pamABC or pamDE, strains KK01
and

KK01csaA

were

transformed

with

the

linearized

disruption

plasmids

pUC19pamABC::kan or pUC19pamDE::kan. To generate pUC19pamABC::kan, DNA
fragments of the homologous recombination targeting sequence corresponding to ~1 kb
upstream of pamA and ~1 kb downstream of pamC were PCR amplified from strain KK01
genomic DNA using primers pam 5’ For/ pamABC 5’ Rev and pamABC 3’ For/ pamABC
3’ Rev, respectively, and were ligated into pUC19. To generate pUC19pamDE::kan, DNA
fragments of the homologous recombination targeting sequence corresponding to ~1 kb
upstream of pamD and ~1 kb downstream of pamE were PCR amplified from strain KK01
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genomic DNA using primers pamDE 5’ For/ pamDE 5’ Rev and pam 3’ For/ pam 3’ Rev,
respectively, and were ligated into pUC19. For both plasmids, a kanamycin resistance
cassette was then ligated into the BamHI site located between the cloned upstream and
downstream homologous recombination targeting sequences.
To generate strain KK143csb, strain KK143 was transformed with the linearized
disruption plasmid pSwapEmpty (Starr, Porsch, Seed, Heiss, et al., 2016). To generate
pamABCDE deletion mutants, strains KK143 and KK143csb were transformed with the
linearized disruption plasmid pUC19pam::ermC (Starr et al., 2013). The plasmids were
purified from E. coli and linearized with NdeI.
To generate pUC19pamABC, DNA fragments were amplified from strain KK01
genomic DNA by PCR using primers pam Amp For/ pamABC Amp Rev and were ligated
into pUC19. Plasmids pUC19EmptyVector and pUC19pamABC were transformed into E.
coli strain DH5a by electroporation, and transformants were recovered by plating on agar
supplemented with 100 µg/ml ampicillin.

Strain
Kingella kingae
KK01
PYKK181
CC254
KK242
KK430
KK143

Table 6: Strains and plasmids used in this study
Description
Nonspreading/noncorroding derivative of
269-492
Clonal group V isolate from patient with
bacteremia
Clonal group V isolate from a healthy
carrier
Clonal group V isolate from patient with
bacteremia
Clonal group V isolate from patient with
bacteremia
Clonal group V isolate patient with of
septic arthritis
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Reference
(Kehl-Fie & St.
Geme III, 2007)
Yagupsky, P.
Yagupsky, P.
Yagupsky, P.
Yagupsky, P.
Yagupsky, P.

KK405
Sch1614
ATCC23330
KK245
KK247
BB060
KK113
AA046
KK86
KK145
KK12
KK136
KK83
BB012
KK142
KK164
KK144
KK190
KK141
AA068
KK245

Clonal group V isolate patient with of
septic arthritis
Clonal group ϑ isolate from a healthy
carrier
Clonal group D isolate from a healthy
carrier
Clonal group A isolate from patient with
bacteremia
Clonal group A isolate from patient with
endocarditis
Clonal group D isolate from a healthy
carrier
Clonal group C isolate from a healthy
carrier
Clonal group F isolate from a healthy
carrier
Clonal group K isolate from a healthy
carrier
Clonal group K isolate from patient with
septic arthritis
Clonal group H isolate from a healthy
carrier
Clonal group H isolate from patient with
bacteremia
Clonal group H isolate from patient with
septic arthritis
Clonal group B isolate from a healthy
carrier
Clonal group B isolate from patient with
septic arthritis
Clonal group P isolate from patient with
bacteremia
Clonal group P isolate from patient with
septic arthritis
Clonal group P isolate from patient with
endocarditis
Clonal group N isolate from patient with
osteomyelitis
Clonal group N isolate from a healthy
carrier
Clonal group A isolate from patient with
bacteremia
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Yagupsky, P.
Yagupsky, P.
ATCC
Yagupsky, P.
Yagupsky, P.
Yagupsky, P.
Yagupsky, P.
Yagupsky, P.
Yagupsky, P.
Yagupsky, P.
Yagupsky, P.
Yagupsky, P.
Yagupsky, P.
Yagupsky, P.
Yagupsky, P.
Yagupsky, P.
Yagupsky, P.
Yagupsky, P.
Yagupsky, P.
Yagupsky, P.
Yagupsky, P.

EE160
BB114
KK01csaA
KK01pam
KK01csaApam
KK01pamABC
KK01pamDE
KK01csaApamABC
KK01ScsaApamDE
KK143csb
KK143pam
KK143csbpam
E. coli
DH5a

Clonal group A isolate from a healthy
carrier
Clonal group A isolate from a healthy
carrier
Derivative of KK01 with deletion of csaA
type a capsule synthesis gene
Derivative of KK01 with deletion of
pamABCDE exopolysaccharide locus
Derivative of KK01 with deletion of csaA
and pamABCDE locus
Derivative of KK01 with deletion of
pamABC locus
Derivative of KK01 with deletion of
pamDE locus
Derivative of KK01 with deletion of csaA
and pamABC locus
Derivative of KK01 with deletion of csaA
and pamDE locus
Derivative of KK143 with deletion of
csbABC type b capsule synthesis locus
Derivative of KK143 with deletion of
pamABCDE exopolysaccharide locus
Derivative of KK143 with deletion of
csbABC and pamABCDE loci
-

E. coli F φ80dlacZ∆M15 ∆(lacZYAargF)U169 deoR recA1 endA1 hsdR17(rK

Yagupsky, P.
Yagupsky, P.
(Starr, Porsch,
Seed, & St.
Geme III, 2016)
(Starr et al.,
2013)
(Muñoz et al.,
2018)
This study
This study
This study
This study
This study
This study
This study
(Sambrook et al.,
1989)

+

mK ) phoA supE441 thi-1 gyrA96 relA1
Plasmid
E. coli
pUC19pam::ermC
pSwapEmpty
pUC19pamABC::kan

Description
pUC19 derivative that contains
pamABCDE disruption construct marked
with the ermC erythromycin cassette
Contains the capsule synthesis locus
flanking genes with the capsule synthesis
variable region deleted
pUC19 derivative that contains pamABC
disruption construct marked with the
aphA3 kanamycin cassette
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Reference
(Starr et al.,
2013)
(Starr, Porsch,
Seed, Heiss, et
al., 2016)
This study

pUC19pamDE::kan
pUC19pamABC

pUC19 derivative that contains pamDE
disruption construct marked with the
aphA3 kanamycin cassette
pUC19 derivative that contains the
pamABC locus and upstream promoter

This study
This study

4.2.3 Polysaccharide extraction and staining
For capsule extractions, K. kingae strains were grown at 37°C with 5% CO2 on
chocolate agar plates. Bacteria were resuspended in PBS to an OD600 ~1.2, and cells were
pelleted, washed, and resuspended in Tris acetate pH 5.0 for 1 hr. Cells were removed by
centrifugation, and extracts were treated with proteinase K for 1 hr and then concentrated
as previously described (Porsch et al., 2012). For capsule and exopolysaccharide copurifications, bacteria were resuspended in 5 ml PBS and vortexed. Cells were removed by
centrifugation, and bacterial supernatants were treated with proteinase K for 1 hr and then
concentrated as previously described (Porsch et al., 2012).
Aliquots of supernatant and purified capsule from K. kingae derivatives were
separated on 7.5% and 10% SDS-PAGE gels, respectively. For supernatant samples, SDSPAGE gels were treated first with silver staining and subsequently with Alcian blue
staining. For purified capsule samples, SDS-PAGE gels were treated with 0.125% Alcian
blue as previously described (Porsch et al., 2012). For silver staining, gels were treated as
previously described (J. S. Kim et al., 1996).
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4.2.4 RNA isolation and RT-PCR
Total RNA from K. kingae strain KK01 was extracted and purified as previously
described (Kehl-Fie et al., 2009). Briefly, RNA was extracted using TRIreagent (Sigma,
St. Louis, MO) and the RNeasy minikit by following the lipid-rich tissue protocol (Qiagen,
Valencia, CA). Residual DNA was removed with RQ1 DNase (Fisher Scientific,
Pittsburgh, PA). The concentration and purity of the RNA were determined by measuring
the A260/A280 ratio with a Nanodrop 2000 (Thermo Fisher, Rockford, IL). The qScript
cDNA SuperMix kit (Quanta Biosciences, Beverly, MA) was used according to the
manufacturer’s instructions for RT-PCR. The primer sets used for RT-PCR are listed in
Table 7.

Primer
pam 5’ For

Table 7: Primers used in this study
Sequence (5’ -3’)
GCGAATTCGGCGTTGGTGGAATATCCTG

pam 3’ For

GCGGATCCTCAAAGGCTGGTATAAACAC

pam 3’ Rev

GCAAGCTTCCATATCGCTTTGGCTTTGC

pamAB
outside Rev
pamA
locator Rev
pam inside
For

GCTTTCGGAATGCTTGCGTACC

This study

GCAGGCTTGATACAGGTCTTTG

This study

GCGACTGTTCCCAATACGATAG

This study
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Reference
(Starr,
Porsch, Seed,
& St. Geme
III, 2016)
(Starr,
Porsch, Seed,
& St. Geme
III, 2016)
(Starr,
Porsch, Seed,
& St. Geme
III, 2016)

pam inside
Rev
01 pamC 5’
For
181 pamC 5’
For
pamC 3’
Rev
pam Amp
For
pamABC
Amp Rev
pamABC 5’
Rev
pamABC 3’
For
pamABC 3’
Rev
pamDE 5’
For
pamDE 5’
Rev
pamD For
pamE Rev

GCATCTGCTGCACGTTGCGTTG

This study

CGGCATTCCTTTGCATCACG

This study

ATCTTATCAATCTATCTGCCATGG

This study

AACGTTGCGACATAGCCTGTG

This study

ACGTGAATTCCGGCGCAAGATTTACAGC

This study

ACGTGGATCCTTTCGGGATATTGCGGTTGG

This study

ACGTGGTACCACCTTCTGGTCGCTGAAATG

This study

ACGTGGATCCCTATGTCGCAACGTTTGATAGG

This study

ACGTAAGCTTGAATGTTGTCCAGCGCAATC

This study

ACGTGAATTCTCGTGCTTATGCGCTGTTGC

This study

ACGTGGTACCTTTCGGGATATTGCGGTTGG

This study

ATTTGGCTTCGCGTGTTG
GGCGTGCCAAATTGAATC

This study
This study

4.2.5 Serum bactericidal assays
K. kingae strains were grown at 37°C with 5% CO2 on chocolate agar plates and
then resuspended in PBS containing 0.1% gelatin (PBS-G). E. coli strains were grown on
LB agar or shaking at 250 rpm in LB broth supplemented with 100 µg/ml ampicillin at
37°C to OD600 0.8. Samples were diluted in PBS-G to obtain a final inoculum of
approximately 4.0 x 103 cfu/0.1 ml. The respective inocula were mixed with pooled NHS
(Immucor, Norcross, GA) or HI-NHS (prepared by incubating NHS at 56°C for 20 min)
diluted in PBS-G, as appropriate, and incubated for various time points at 37°C with 5%
100

CO2. Serial dilutions of the inoculum and reaction samples were plated on chocolate agar
plates and incubated overnight at 37°C with 5% CO2 to determine cfu counts (limit of
detection for plating: 20 cfu).

4.2.6 Statistical analysis
Statistical analyses were performed with GraphPad Prism (version 7.0a) software
for Mac (GraphPad Software, San Diego, CA), where a P value of <0.05 was considered
statistically significant. The specific statistical tests used for each experiment are specified
in the figure legends.

4.3 Results
4.3.1 Exopolysaccharide purification and visualization
In order to extract and co-purify the polysaccharide capsule and exopolysaccharide,
we collected bacterial supernatants from K. kingae strains KK01, KK01csaA, KK01pam,
and KK01csaApam in 5 ml PBS. After concentration and proteinase K treatment,
supernatants were separated on 7.5% SDS-PAGE gels (Fig. 18). The polysaccharide
capsule from the surface of strains KK01 and KK01pam stained prominently with silver
stain and Alcian blue reagents (Fig. 18), as demonstrated previously (Starr et al., 2013).
The exopolysaccharide capsule from the surface of strains KK01 and KK01csaA stained
prominently with silver stain but did not stain with Alcian blue (Fig. 18, data not shown).
The supernatant from strain KK01csaApam failed to stain with either silver stain or Alcian
blue reagents, as expected (Fig. 18).
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Figure 18: Silver and Alcian blue staining of K. kingae surface polysaccharides
present in bacterial supernatants.
Samples were proteinase K treated and resolved on a 7.5% SDS-PAGE gel. Lane 1,
protein ladder, molecular sizes in kDa; lane 2, strain KK01; lane 3, strain KK01csaA;
lane 4, strain KK01pam; lane 5, strain KK01csaApam.

4.3.2 KK01 pamABC is sufficient for serum resistance.
Previous work determined that expression of pamABC from K. kingae clinical
isolate PYKK181 in E. coli was sufficient for inhibiting biofilm formation (Bendaoud et
al., 2011). To determine whether pamD and pamE were necessary for exopolysaccharidemediated serum resistance, we performed serum bactericidal assays using human serum.
We deleted the entire pam locus (pamABCDE), or portions of the pam locus (pamABC or
pamDE) in either strain KK01 or strain KK01csaA. Inocula of 1.0 x 103 cfu were incubated
for 1 hr with 50% human serum (Fig. 19), using strain KK01csaApam (containing a
deletion of pamABCDE) as a serum-sensitive control. To assess serum sensitivity, a
survival ratio was calculated, dividing the number of cfu recovered from NHS by the
number of cfu recovered from HI-NHS.
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Figure 19: Deletion of pamD and pamE does not affect K. kingae serum resistance in
the absence of capsule.
K. kingae strains KK01, KK01pam, KK01csaApam, KK01pamABC,
KK01csaApamABC, KK01pamDE, and KK01csaApamDE were incubated with 50%
NHS or 50% HI-NHS for 1 h. The survival ratio was calculated by dividing the NHS
CFU counts by the HI-NHS CFU counts. A total of three biological replicates were
performed (n = 3). Statistical significance was determined with an unpaired Student’s
t test, and the error bars represent the standard error of the mean. *, P < 0.05.
Deletion of pamABC or pamDE resulted in no growth defects on solid agar and had
no effect on survival in the presence of 50% HI-NHS. Survival in 50% NHS by strains
KK01pam, KK01pamABC, KK01pamDE, and KK01csaApamDE was not significantly
different from the survival of wild-type strain KK01 (Fig. 19). In contrast, survival in 50%
NHS by strains KK01csaApam and KK01csaApamABC was markedly reduced, with a
survival ratio of ~0.40 (P < 0.05, Fig. 19).
To further confirm that the KK01 pamABC genes promote serum resistance, we
transformed E. coli strain DH5a with either an empty vector pUC19 plasmid or the
pUC19pamABC plasmid. Due to the sensitivity to serum of strain DH5a, the serum
resistance assays were performed by incubating DH5a derivatives with 2% human serum
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for 30 min (Fig. 20). Five individual transformants harboring the pUC19pamABC plasmid
were selected and assessed for changes in serum resistance, using DH5a/pUC19 as a
serum-sensitive control. We observe in our preliminary data (n=2) that the survival ratio
of DH5a/pUC19 in 2% NHS was ~0.18 (Fig. 20). In contrast, the survival ratio of
DH5a/pUC19pamABC clones 1-3 in 2% NHS was much higher, between 0.55-0.70 (Fig.
20). The survival ratio of DH5a/pUC19pamABC clones 4 and 5 in 2% NHS was
moderately increased, approximately ~0.40 (Fig. 20).

Figure 20: Expression of the KK01 pamABC genes in serum-sensitive E. coli increases
serum resistance.
E. coli strains DH5a/pUC19 (Vector) and DH5a/pUC19pamABC were incubated with
2% NHS or 2% HI-NHS for 30 min. The survival ratio was calculated by dividing the
NHS CFU counts by the HI-NHS CFU counts. A total of three biological replicates
were performed (n = 2).
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So far, these results establish that the pamABC genes are sufficient to promote
serum resistance and confirm that pamD and pamE are not critical for exopolysaccharidemediated serum resistance in K. kingae and E. coli.

4.3.3 Transcriptional analysis of KK01 pam locus.
To determine expression of polycistronic transcripts in the exopolysaccharide
biosynthesis locus, the transcription of K. kingae strain KK01 pamA, pamB, pamC, pamD,
and pamE was assessed by RT-PCR. We performed RT-PCR from K. kingae KK01 cDNA
using three forward primers that fall within the pamA, pamC, or pamD open reading frames
(ORF) and four reverse primers within the pamB, pamC, pamD, or pamE ORF (Fig. 21A).
Using Virtual Footprint analysis, predicted promoters were upstream of the pamA and
pamD genes; no terminator sequences were detected within the pamABCDE locus (Münch
et al., 2005). We detected amplicons of the expected size when using the specific primers
for the contiguous genes pamAB, pamABC, pamCDE, pamCD, and pamDE (Fig. 21B-D).
Conversely, amplicons were less abundant when using specific primers for the contiguous
genes pamABCD and pamABCDE (Fig. 21B, C).
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Figure 21: Transcription and polycistronic mRNA of pamABCDE locus in K. kingae
strain KK01.
Genomic structure of K. kingae pamABCDE genes and surrounding genes (A).
Specific primers for RT-PCR designed to amplify PCR products are shown in arrows
(forward primers, red; reverse primers, black). Polycistronic mRNA PCR products
for pamAB, pamABC, pamABCDE, (B) pamABCDE, pamDE, (C), pamCD, and
pamCDE (D). Lane 1, genomic DNA; Lane 2, cDNA; Lane 3, no reverse transcriptase
(RT).
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4.3.4 The type 1 and type 2 exopolysaccharides are associated with two
distinct PamC proteins.
Previous work determined that the septic arthritis clinical isolate KK01 expresses a
à5)-β-Galf-(1à galactan homopolymer designated as a type 1 exopolysaccharide,
whereas the bacteremia clinical isolate PYKK181 expresses a à3)-β-Galf-(1à5)-β-Galf(1à galactan homopolymer designated as a type 2 exopolysaccharide. To determine
whether the differences in polymer linkages were due to genes present in the pam locus,
we performed amino acid sequence alignments to compare the percent identity and
similarity of the predicted PamA, PamB, PamC, PamD, and PamE proteins across the two
K. kingae strains. This comparison revealed a lower percent identity and similarity between
PamC alleles relative to the other proteins encoded by the pamABCDE locus, with an
overall identity of 85% and a similarity of 91% (Fig. 22). The identity and similarity of
PamA and PamB between strains was 99% (Fig. 22), the identity and similarity of PamD
between strains was 100% (Fig. 22), and the identity and similarity of PamE between
strains was 98% (Fig. 22).

Figure 22: Comparison of the predicted protein products of the pam genes in K. kingae
strains KK01 and PYKK181.
Genomic organization of the pamABCDE loci in K. kingae strains KK01 (top) and
PYKK181 (bottom). The light blue boxes highlight the identity and similarity based
on amino acid sequence alignments of the predicted PamA, PamB, PamC, PamD, and
PamE proteins (center); one number is denoted if the percent identity and similarity
are the same.
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Based on BLAST analyses, PamC is a predicted galactofuranosyl transferase, with
potential to create linkages in polymer chains. Further analysis of the 592 amino acid PamC
protein revealed a 146-amino acid stretch with relatively low identity (46%) and low
similarity (67%) when comparing strain KK01 to strain PYKK181 (Fig. 23). Of the 55
non-synonymous amino acid changes between strain KK01 PamC and strain PYKK181
PamC, 48 were present in this 146-amino acid stretch of low homology (Fig. 23). These
results suggest that PamC is the molecular determinant of exopolysaccharide diversity in
K. kingae clinical isolates.

Figure 23: Comparison of PamC across K. kingae strains KK01 and PYKK181.
Schematic highlighting a region of low identity and similarity between KK01 PamC
(blue) and PYKK181 PamC (red) (A). The light blue boxes highlight the identity and
similarity between the full-length PamC proteins (A) and the 146-amino acid PamC
fragments (B). Predicted amino acid sequence alignment of KK01 PamC (top) and
PYKK181 PamC (bottom) highlighting the region with the lowest amount of
homology (pink) (C).
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4.3.5 pamC1 is predominant in clinical isolates of K. kingae.
To determine the presence of the KK01 pamC allele (pamC1) or the PYKK181
pamC allele (pamC2) in K. kingae clinical isolates, we designed allele-specific forward
primers that anneal within the variable region of the pamC gene and a reverse primer that
anneals within a conserved region of the pamC gene, producing allele-specific amplicons
(Fig. 24A). PCR amplification of genomic DNA from K. kingae strains KK01, PYKK181,
and KK01pam confirmed primer specificity to either the pamC1 or pamC2 allele (Fig.
24B).

Figure 24: K. kingae pamC allele PCR-typing method.
Illustration of pamC alleles of K. kingae strains KK01 and PYKK181 highlighting the
variable region in pamC1 (blue) and pamC2 (red) (A). Specific primers designed are
shown in arrows (allele-specific forward primer, blue or red; conserved reverse
primer, black). PCR amplification of strains KK01pam, KK01, and PYKK181 using
the pamC1-specific forward primer (top) or the pamC2-specific forward primer
(bottom). Lane 1, DNA ladder; Lane 2, KK01pam; Lane 3, KK01; Lane 4, PYKK181.
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Using the pamC allele PCR-typing method, we screened a collection of 24 clinical
isolates for the presence of the pamC1 or pamC2 allele. The 24 clinical isolates represent
14 sequence types based on multilocus sequence typing; 12 of the 14 sequence types are
clustered into seven sequence type complexes (two of the sequence types represented do
not fall into a sequence type complex) (Basmaci et al., 2014). Additionally, based on
previous PFGE analysis, the clinical isolates represent 11 PFGE clonal groups (A, B, C F,
H, K, N, P, V, and ϑ), including the five major clonal groups that account for >72% of
invasive disease isolates (B, H, K, N, and P) (Amit et al., 2012; Starr, Porsch, Seed, Heiss,
et al., 2016). The cohort represents 12 strains from healthy carriers and 12 strains from
patients with invasive disease, including bacteremia (5), septic arthritis (4), endocarditis
(2), and osteomyelitis (1) (Basmaci et al., 2014).
Amplicons were detected in all of the clinical isolates screened for one of the two
pamC alleles (Fig. 25). The pamC1 allele was predominant among clinical isolates, present
in 87.5% (21 of 24) of these strains (Fig. 25). The pamC2 allele was present in the other
three clinical isolates screened (3 of 24, 12.5%) (Fig. 25). All three clinical isolates
containing the pamC2 allele, K. kingae strains CC254, KK242, and Sch1614, fall within
the same sequence type as strain PYKK181.

These data suggest that the type 1

exopolysaccharide is the predominant exopolysaccharide present in K. kingae clinical
isolates. No significant associations between exopolysaccharide type and clinical
presentation were identified. Clinical isolates present in this study had been examined
previously for capsule type (Starr, Porsch, Seed, Heiss, et al., 2016); however, no
significant associations between exopolysaccharide type and capsule type were found.
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Figure 25: PCR screening of a diverse cohort of K. kingae clinical isolates.
PCR amplification of genomic DNA from K. kingae strains using the pamC1-specific
forward primer (top) or the pamC2-specific forward primer (bottom). K. kingae
strains KK01pam, KK01, and PYKK181 were used as controls. Color blocks above
image represent clinical isolates present in a similar sequence type (red or purple) or
sequence type complex (pink, orange, yellow, blue, green, sky, or navy). Lane 1,
ATCC 23330; Lane 2, BB060; Lane 3, AA046; Lane 4, KK86; Lane 5, KK145; Lane
6, KK12; Lane 7, KK136; Lane 8, KK83; Lane 9, BB012; Lane 10, KK142; Lane 11,
KK98; Lane 12, KK164; Lane 13, KK144; Lane 14, KK190; Lane 15, CC254; Lane
16, KK242; Lane 17, Sch1614; Lane 18, KKBB114 ; Lane 19, KK245; Lane 20,
EE160; Lane 21, KK247; Lane 22, KK141; Lane 23, AA068; Lane 24, KK113.

4.3.6 pamC2 is present in PFGE V clinical isolates.
To determine whether clinical isolates within the same PFGE group as K. kingae
strain PYKK181 possess the pamC2 allele, we used the pamC allele PCR-typing method
to screen a collection of six clinical isolates present within the PFGE V or ϑ group. The
cohort was comprised of two healthy carrier isolates and four invasive isolates, including
isolated associated with bacteremia (2) and septic arthritis (2). The pamC1 allele was
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present in 0% (0 of 6) of all clinical isolates screened (Fig. 26). The pamC2 allele was
present in 100% (6 of 6) of all clinical isolates screened (Fig. 26). These results suggest
that the pamC2 allele may be restricted to a distinct set of clinical isolates. Interestingly,
all clinical isolates within these two PFGE groups express a type b polysaccharide capsule;
however, based on Fig. 25, clinical isolates that produce a type b capsule may contain either
the pamC1 or pamC2 allele.

Figure 26: PCR screening of PFGE V K. kingae clinical isolates.
PCR amplification of K. kingae strains using the pamC1-specific forward primer (top)
or the pamC2-specific forward primer (bottom). K. kingae strains KK01pam, KK01,
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and PYKK181 were used as controls. Lane 1, CC254; Lane 2, KK242; Lane 3,
KK430; Lane 4, KK143; Lane 5, KK405; Lane 6, Sch1614.

4.3.7 Both type 1 and type 2 exopolysaccharides confer serum
resistance.
To determine whether the type 2 exopolysaccharide also confers serum resistance
in the absence of the polysaccharide capsule, we performed serum bactericidal assays using
derivatives of K. kingae strain KK143, a septic arthritis clinical isolate producing a type b
capsule and possessing the pamC2 allele. Unlike K. kingae strain PYKK181, K. kingae
strain KK143 was amenable to genetic manipulation. Serum bactericidal assays were
performed using strain KK143, strain KK143csb (a capsule-deficient mutant lacking the
csbABC capsule synthesis locus), strain KK143pam (an exopolysaccharide-deficient
mutant lacking the pamABCDE galactan exopolysaccharide synthesis operon), and strain
KK143 csbpam (a double mutant lacking both capsule and exopolysaccharide synthesis
genes). Assays were performed using 50% serum for 1 hr, and strains KK01, KK01csaA,
KK01pam, and KK01csaApam were used as controls (Fig. 27A). Deletion of csb, pam, or
both csb and pam resulted in no growth defects on solid agar and had no effect on survival
in the presence of 50% HI-NHS. Survival in 50% NHS of strains KK143csb and
KK143pam was not significantly different from the survival of wild-type strain KK143
(Fig. 27B). In contrast, survival in 50% NHS by strain KK143csbpam was markedly
reduced, with a survival ratio of less than 0.35 (P < 0.05, Fig. 27B).
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Figure 27: The type 2 exopolysaccharide promotes serum resistance for K. kingae
strain KK143.
K. kingae strains KK01, KK01csaA, KK01pam, KK01csaApam, (B) KK143,
KK143csb, KK143pam, and KK143csbpam (B) were incubated with 50% NHS or
50% HI-NHS for 1 h. The survival ratio was calculated by dividing the NHS CFU
counts by the HI-NHS CFU counts. A total of three biological replicates were
performed (n = 3). Statistical significance was determined with an unpaired Student’s
t test, and the error bars represent the standard error of the mean. *, P < 0.05.
These results establish that in the absence of the polysaccharide capsule, the type 2
exopolysaccharide is critical for survival in the presence of human serum, similar to
observations with the type 1 exopolysaccharide.

4.4 Discussion
Polysaccharide-conjugate vaccines against Haemophilus influenzae, Neisseria
meningitidis, and Streptococcus pneumoniae have provided long-lived protection,
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reflecting stimulation of robust immune responses in infants (Goldblatt, 2000; Hyams et
al., 2010; Moxon & Kroll, 1988; Swartley et al., 1997). Polysaccharide-conjugate vaccine
design is typically guided by polysaccharide capsule diversity and correlation with invasive
disease (Goldblatt, 2000). Analyses of a large collection of K. kingae clinical isolates
revealed four distinct capsule structures and capsule biosynthesis loci, two of which
account for >95% of invasive disease cases (Porsch et al., 2017; Starr, Porsch, Seed, Heiss,
et al., 2016). Identification of the polysaccharide capsule led to the discovery of the
exopolysaccharide, which has a distinct polymer structure separate from the polysaccharide
capsule (Starr et al., 2013). In this study, we hoped to enhance understanding of the
exopolysaccharides produced by K. kingae to better evaluate the potential of this factor as
a vaccine candidate.
Previous work from Bendaoud et al. utilized an inducible plasmid containing the
pamABC locus from K. kingae strain PYKK181 in E. coli and demonstrated
exopolysaccharide production and anti-biofilm properties (Bendaoud et al., 2011). Using a
high copy number plasmid, we were able to demonstrate that expression of the strain KK01
pamABC genes in E. coli promoted serum resistance, further confirming the importance of
the exopolysaccharide in preventing complement-mediated lysis. It is interesting to note
that expression of the pamABC biosynthesis locus alone was sufficient for biofilm dispersal
and serum resistance in E. coli, unlike the K. kingae polysaccharide capsule biosynthesis
locus, which requires additional genes necessary for lipidation and capsule export
(Bendaoud et al., 2011; Starr, Porsch, Seed, & St. Geme III, 2016).
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Based on previous work and data from this study, PamD and PamE are not essential
for exopolysaccharide biosynthesis, serum resistance, or biofilm dispersal (Bendaoud et
al., 2011). Based on BLAST analyses, PamD and PamE are predicted putative
glycosyltransferases. There is a predicted promoter binding site upstream of pamD,
suggesting that pamD and pamE are separate from the pam exopolysaccharide biosynthesis
locus. Unpublished data suggest that pamD and pamE affect K. kingae lipopolysaccharide
(LPS) biosynthesis; however, it is unclear to what extent. Deletion of the pamABC locus
did not visibly alter the LPS migration pattern, providing further evidence for distinct roles
for the pamABC and pamDE genes (unpublished data). In ongoing studies, LPS
purification and analysis will clarify the role of the pamD and pamE genes.
Previous descriptions of the pam loci between K. kingae strains KK01 and
PYKK181 noted high homology within the pamABCDE gene cluster; however, individual
predicted amino acid sequence alignments of the five gene products revealed significant
differences in the pamC products, suggesting that these gene products may be the
molecular determinant of exopolysaccharide diversity. PCR-typing of the pamC alleles
identified the pamC1 allele (type 1 exopolysaccharide) as predominant in the clinical
isolates screened; although 11 PFGE clonal groups were represented, expanding our
screening to a larger collection of isolates would provide a broader view of
exopolysaccharide diversity . Interestingly, the pamC2 allele was predominant in the PFGE
V clonal group. The PFGE V clonal group contained both carrier and invasive isolates with
the pamC2 allele. Despite the lack of correlation between clinical presentation and
exopolysaccharide type, use of the infant rat infection model may provide better insight to
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differences in exopolysaccharide virulence properties in vivo. Further genetic manipulation
is needed to confirm the function and properties of the two exopolysaccharide types and
pamC alleles.
The lack of cross-protection against antigenically distinct, encapsulated strains is a
limitation of capsule-conjugate vaccines. Recently through the use of genomic sequencing,
outer membrane proteins have been targeted as vaccine antigens in a variety of pathogens
due to the conservation across strains (Etz et al., 2002; Pizza et al., 2000; Tan, Carlone, &
Borrow, 2010; Wizemann et al., 2001). We demonstrate the presence of only two
exopolysaccharide loci in K. kingae strains, with a majority of clinical isolates containing
the type 1 exopolysaccharide locus, thus providing further evidence of the
exopolysaccharide as an attractive vaccine candidate.
The type 1 exopolysaccharide had been previously described as promoting K.
kingae survival in human serum. Through the generation of surface polysaccharide mutants
in K. kingae strain KK143, we were able to confirm that the type 2 exopolysaccharide
exhibits similar properties. Exopolysaccharide pam swap constructs will be created to
further confirm the galactofuranosyl transferase activity of pamC and to express the type 1
and type 2 exopolysaccharides in an isogenic background for functional analyses in future
experiments.
To summarize, in this study we have established a SDS-PAGE staining protocol
for visualization of co-purified surface polysaccharides and a pamC PCR-typing method.
Analyses of the pam loci confirmed that pamABC is sufficient to promote serum resistance
in both K. kingae as well as in E. coli. PCR-typing allowed us to determine the level of
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diversity in the pamC allele across a collection of 27 K. kingae clinical isolates and confirm
the presence of only two pamC alleles thus far. We were able to demonstrate that the type
2 exopolysaccharide also functions to protect K. kingae against complement-mediated
lysis. Future studies will focus on exopolysaccharide antigenicity and in vivo infection
studies.
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5. Future Directions
5.1 Conclusion
K. kingae displays high levels of resistance to innate immune components,
specifically to complement- and neutrophil-mediated killing. The data presented in
Chapters 2 and 3 demonstrate the significance of surface polysaccharides (the
polysaccharide capsule and exopolysaccharide) in K. kingae immune evasion and virulence
in vivo. Chapter 4 delves into the biosynthesis locus of the exopolysaccharide and explores
the diversity of the exopolysaccharide present in K. kingae clinical isolates. The future
directions and experimental approaches outlined below will identify and characterize other
determinants of innate immune evasion in K. kingae. Moreover, we will investigate the
multi-faceted functions of the K. kingae surface polysaccharides in immune evasion and
begin to provide better insight into polysaccharide diversity and its contribution to K.
kingae pathogenicity.

5.2 Evaluate the impact of polysaccharide capsule diversity on immune
evasion
Capsule production by invasive pathogens promotes host survival by inhibiting
complement activation and neutrophil recognition (Beiter et al., 2008; Campos et al., 2004;
Hallström & Riesbeck, 2010; Hyams et al., 2010; Lambris et al., 2008; Wartha et al., 2007).
Many species of bacteria express multiple different capsule serotypes, and in some cases a
specific capsule type is associated with invasive disease potential, as is the case with H.
influenzae serotype b capsule (Cochi, Broome, & Hightower, 1985) and Klebsiella
pneumoniae capsule types K1 and K2 (Mizuta et al., 1983; Paczosa & Mecsas, 2016). K.
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kingae clinical isolates can be classified into four distinct capsule types (types a, b, c, and
d) (Starr, Porsch, Seed, Heiss, et al., 2016). Strains expressing the type a and type b capsule
account for >95% of invasive disease isolates (Porsch et al., 2017; Starr, Porsch, Seed,
Heiss, et al., 2016), suggesting that the distinct capsule composition may play a role in the
pathogenicity of K. kingae.
As previously shown in Chapters 2 and 3, K. kingae strain KK01 expresses a type
a polysaccharide capsule that protects K. kingae against complement- and neutrophilmediated killing (Muñoz et al., 2018). Furthermore, isogenic derivatives of strain
KK01pam expressing one of the four capsule types were associated with a serum survival
ratio similar to the serum survival ratio for strain KK01 (the parental strain) (Muñoz et al.,
2018). To assess whether the four capsule types differentially protect K. kingae against
neutrophil-mediated killing, we performed neutrophil killing assays on isogenic derivatives
of strain KK01pam expressing either capsule type a (strain KK01Swapcsapam), capsule
type b (strain KK01Swapcsbpam), capsule type c (strain KK01Swapcscpam), or capsule
type d (strain KK01Swapcsdpam). The survival of strains KK01pam, KK01pamSwapcsa,
KK01pamSwapcsb, KK01pamSwapcsd was not affected at an MOI of 0.1 in the presence
of neutrophils with 1% HSA or 1% NHS (Fig. 28A-C, E). The survival of strain
KK01pamSwapcsc was slightly affected at an MOI of 0.1 in the presence of neutrophils
with 1% NHS (Fig. 28D). As expected, survival of strain KK01pamSwapEmpty was
significantly decreased at an MOI of 0.1 in the presence of neutrophils with 1% HSA and
1% NHS (Fig. 28F). These data suggest that the presence of any of the four naturally
occurring K. kingae capsule type is adequate in serving a protective role for K. kingae strain
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KK01 under in vitro serum and neutrophil experiments. Future studies will investigate the
slight changes in neutrophil sensitivity when the type c capsule is expressed in the
KK01Swap background.

Figure 28: The four distinct capsule types of K. kingae promote neutrophil survival
in isogenic strain derivatives.
K. kingae strain KK01pam (A), or isogenic derivatives of strain KK01pam expressing
either capsule type a (Swapcsapam) (B), capsule type b (Swapcsbpam) (C), capsule
type c (Swapcscpam) (D), capsule type d (Swapcsdpam) (E), or an empty cassette
(SwapEmptypam) (F) were incubated with (white bars) or without (colored bars)
neutrophils in the presence of 1% HSA or 1% NHS at an MOI of 0.1. The percent
survival was calculated by dividing the cfu counts by the inoculum. Statistical
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significance was determined using two-way analysis of variance and the Tukey post
hoc test. The error bars represent the SEM of 3 independent experiments. *P <0.05;
**P <0.01; ***P <0.001.
Given the correlation between K. kingae capsule type and clinical presentation, we
are interested in elucidating the virulence phenotype of capsule isogenic derivatives in vivo.
To examine the virulence potential of the distinct K. kingae capsule types, we will use a
previously described juvenile rat infection protocol (Starr, Porsch, Seed, & St. Geme III,
2016). Briefly, five-day-old Sprague-Dawley rat pups will be injected via the
intraperitoneal (i.p.) route with KK01 and KK01pam isogenic capsule swap strains.
Morbidity and mortality will be monitored over a five-day period. We hypothesize that the
K. kingae isogenic derivatives expressing either capsule type a or capsule type b will be
more virulent in an in vivo infant rat infection model than isogenic derivatives expressing
either capsule type c or capsule type d.
Anti-capsular antibodies promote opsonization and lead to efficient complement
and neutrophil activation as previously demonstrated in H. influenzae and K. pneumoniae
(Jacob Amir, Liang, & Granoff, 1990; Anderson R. B., Jr.; Smith, D. H., 1972; Johnston,
Anderson, Rosen, & Smith, 1973; Kobayashi et al., 2018). Currently, antisera against
purified K. kingae capsular material conjugated to an immunogenic carrier protein is being
generated in guinea pigs. ELISA analyses demonstrate the specificity of the K. kingae anticapsule antibodies to their respective capsule type (data not shown). To determine whether
K. kingae anti-capsule antibodies enhance killing of encapsulated K. kingae, we will
perform serum resistance and neutrophil-killing assays using capsule isogenic derivative
strains in the presence of anti-capsule antibodies generated against the type a, b, c, or d
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capsule. We predict that preincubation with anti-capsule antibodies will promote
complement and neutrophil activation and enhance killing of encapsulated K. kingae
strains. Additionally, in vivo administration of anti-capsule antibodies will be used in the
juvenile rat infection model as a passive immunization strategy against K. kingae infection.
We hypothesize that passive immunization will lead to attenuation of encapsulated K.
kingae strains in our in vivo model.
In H. influenzae and K. pneumoniae, capsule overproduction is associated with
disease and hypervirulent strains (Dorman, Feltwell, Goulding, Parkhill, & Short, 2018;
Noel et al., 1996, 1992; Paczosa & Mecsas, 2016; Shon, Bajwa, & Russo, 2013; Swift et
al., 1991). Earlier studies utilized atomic force microscopy to determine the average depth
of the K. kingae type a capsule in strain KK01 (Kern et al., 2017). Evaluation of KK01
capsule isogenic derivative strains as well as clinical isolates from both invasive and carrier
strains using atomic force microscopy may provide valuable insight into differences in
capsule production and expression between the four capsule types and across a diverse
cohort of K. kingae strains.

5.3 Binding of complement regulators and contribution to K. kingae
serum resistance
Complement activation is highly inflammatory and can cause host tissue damage;
therefore, the three complement pathways are highly regulated through a variety of effector
proteins to prevent aberrant activation (Zipfel & Skerka, 2009). So far, over 20 soluble and
surface-bound effector proteins have been identified, including C4b-binding protein
(C4BP), factor H, and vitronectin. C4BP and factor H act as cofactors for factor I
123

recruitment; factor I mediates degradation of C4b and C3b (Blom et al., 2004a; Blom,
Villoutreix, & Dahlbäck, 2004b; Józsi & Zipfel, 2008; Rodríguez de Córdoba, EsparzaGordillo, Goicoechea de Jorge, Lopez-Trascasa, & Sánchez-Corral, 2004). Degradation
of C4b and C3b accelerates the decay of C3 convertases, C4b2a and C3bBp, respectively.
Vitronectin is present in plasma and considered an important component of the
extracellular matrix; vitronectin functions to prevent insertion of the membrane attack
complex into bacterial membranes (Preissner & Seiffert, 1998). Pathogenic bacteria can
exploit complement regulation through the acquisition of these soluble effectors. N.
meningitidis and N. gonorrhoeae (members of the Neisseriaceae family) bind factor H to
prevent activation of the alternative pathway (Lewis et al., 2012; Ram, Sharma, et al.,
1998). We hypothesized that K. kingae, a member of the Neisseriaceae family, binds factor
H, promoting survival of the bacterium even in the absence of surface polysaccharides.
To investigate whether K. kingae binds complement regulator factor H, we
performed flow cytometry assays to determine relative levels of factor H deposition on the
K. kingae surface using human serum as a source for factor H. In comparison to E. coli
strain DH5a, there was a significant increase in factor H deposition on the bacterial
surfaces of K. kingae strains KK01, KK01csaA, KK01pam, and KK01csaApam when
incubated with either 1% or 5% HI-NHS (Fig. 29). Interestingly, deletion of the
exopolysaccharide biosynthesis locus, pam, led to a significant increase in factor H
deposition, although it remains unknown as to why this occurs (Fig. 29). The data
demonstrate that factor H is deposited on the surface of K. kingae and that presence of the
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exopolysaccharide either hinders antibody recognition of surface-bound factor H or
inhibits factor H binding.

Figure 29: Complement regulator, factor H, is present on the K. kingae surface after
serum incubation.
Binding of factor H to the bacterial surface of K. kingae strains KK01, KK01csaA,
KK01pam, KK01csaApam and E. coli strain DH5a was determined using flow
cytometry. Cells were stained with propidium iodine (PI) prior to analysis; 30,000
propidium iodine-positive events per biological replicate were analyzed, and a total
of three biological replicates were performed (n = 3). The percentages represent
events that registered as Alexa Fluor 488 positive (AF-488+). Dark red bars, 5% HINHS; Red bars, 1% HI-NHS; gray bars, secondary antibody-only controls (these bars
are negligible in size due to the low signal).
Using protein blast alignment against K. kingae, we uncovered glycoprotein 2
(GP2), which has predicted homology to the N. meningitidis factor H binding protein
(FHBP). K. kingae GP2 is 21.2% identical and 34.2% similar to N. meningitidis FHBP and
using Phyre2 structural analysis shows 18-27% identity to FHBP (Kelley, Mezulis, Yates,
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Wass, & Sternberg, 2015). To investigate whether GP2 is necessary for factor H binding,
we generated GP2-deletion strains in the K. kingae strains KK01, KK01csaA, KK01pam,
and KK01csaApam. Using the KK01 GP2-deficient strains, we performed flow cytometry
assays to determine relative levels of factor H deposition on the K. kingae bacterial surface
s. There was no change in factor H deposition when GP2 was present or absent (data not
shown). This result suggests that either GP2 is not necessary for factor H-binding or that
K. kingae expresses additional surface structures that promote factor H deposition.
To determine whether GP2 was necessary for K. kingae serum resistance, we
performed serum bactericidal assays using GP2-deficient strains and KK01csaApam as a
serum-sensitive control. No changes in the survival ratio were observed in the GP2deficient strains when compared to KK01 (data not shown). No further analyses were
performed using the GP2-deficient strains.
Unpublished data from the lab determined that the trimeric autotransporter, Knh,
was necessary for adherence to vitronectin-coated plates. Vitronectin is present in human
serum and is a regulator of the terminal complement pathway (Preissner & Seiffert, 1998).
To determine the role of Knh in K. kingae serum resistance, we performed serum
bactericidal assays using strains KK01, KK01csaApam, and Knh-deficient mutants. No
changes in the survival ratio were observed in the Knh-deficient strains when compared to
the parental strain (data not shown). To investigate whether Knh is necessary for factor H
binding, we performed flow cytometry assays to determine relative levels of factor H
deposition on the K. kingae surface in KK01 Knh-deficient strains. There was no change
in factor H deposition when Knh was present or absent (Fig. 30). This result suggests that
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either Knh is not necessary for factor H-binding or that K. kingae expresses additional
surface structures that promote factor H deposition. Knh and GP2 double mutants have not
been generated.

Figure 30: Elimination of the trimeric autotransporter, Knh, does not affect factor
H deposition.
Binding of factor H to the bacterial surface of K. kingae strains KK01, KK01knh,
KK01csaApam, and KK01csaApamknh was determined using flow cytometry. Cells
were stained with propidium iodine (PI) prior to analysis; 30,000 propidium iodinepositive events per biological replicate were analyzed, and a total of three biological
replicates were performed (n = 3). The percentages represent events that registered
as Alexa Fluor 488 positive (AF-488+). Red bars, 1% HI-NHS; gray bars, secondary
antibody-only controls (these bars are negligible in size due to the low signal).
Future studies will determine whether vitronectin and C4BP are deposited on the
bacterial surface of K. kingae using the previously described flow cytometry assays.
Additionally, we will perform serum resistance assays using depleted serum to determine
the necessity of factor H, C4BP, and vitronectin deposition for K. kingae survival in the
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presence or absence of surface polysaccharides. While the loss of capsule and
exopolysaccharide promotes activation of the classical pathway through antibody
deposition, the deposition of factor H and vitronectin may inhibit the alternative and
terminal pathways to promote a low level of survival as demonstrated in Ch. 2. We
hypothesize that K. kingae will be less resistant to human serum when complement
regulators have been depleted from the serum.

5.4 Tn-seq analyses for additional K. kingae immune evasion factors
5.4.1 Complement evasion
Our previous work demonstrates that the elimination of both the capsule and
exopolysaccharide resulted in reduced resistance to complement-mediated lysis (Ch. 2)
(Muñoz et al., 2018). Interestingly, elimination of these surface polysaccharides did not
completely render the K. kingae bacterium sensitive to human serum, suggesting that K.
kingae employs additional factors to prevent membrane attack complex formation and
complement-mediated lysis.
To determine additional factors that mediate serum resistance in the absence of
surface polysaccharides, we generated a K. kingae transposon (Tn) mutant library in strain
KK01csaApam (Fig. 31A). The current mutant library contains ~42,000 random
transposon mutants, an approximate 21x coverage of the K. kingae genome. Serum survival
assays were performed using 1 x 107 bacteria from the pooled mutant library in 20% NHS
or HI-NHS (Fig. 31B). Genomic DNA was recovered from four technical replicates in
three separate experiments. In on-going experiments, we are processing purified genomic
DNA for high-throughput sequencing, which will be used to identify transposon insertions
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that are reduced or absent in the challenge condition (20% NHS). Candidate targets will be
subjected to deletion and complementation to confirm the serum-sensitive phenotype.

Figure 31: Schematic representation of Tn-seq screen for K. kingae survival in human
serum.
Generation of K. kingae mutant library by using the Himar transposase to introduce
random transposon insertions into the K. kingae genome (A). Mutated DNA is then
transformed back into K. kingae. Mutant library is challenged using 20% NHS or
20% HI-NHS and recovered DNA is processed and mapped using Illumina
sequencing (B). Figure adapted from (van Opijnen, Bodi, & Camilli, 2009) and
(Langereis, 2014).

5.4.2 Neutrophil evasion
The previously generated transposon mutant library described in Ch. 5 sub-section
5.4.1 may be utilized in neutrophil-killing assays to determine additional factors necessary
for K. kingae neutrophil evasion in the absence of the polysaccharide capsule and
exopolysaccharide. Tn-seq screens have been performed previously in nontypeable H.
influenzae (NTHi) to elucidate LOS-modifying proteins that protect NTHi in the presence
of neutrophils (Langereis & Weiser, 2014). Additionally, assays will be performed in the
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absence or presence of human serum to identify candidate genes that prevent neutrophilmediated killing in the presence of serum opsonins.

5.5 Determine mechanism of capsule inhibition of neutrophil ROS
production
Elimination of the K. kingae capsule stimulates a rapid and robust release of
reactive oxygen species (ROS) by human neutrophils during K. kingae infection (Ch. 3).
In the absence of the K. kingae polysaccharide capsule, increased neutrophil recognition of
bacterial LPS may prompt TLR4 activation and subsequent ROS production. TLR4 is
activated by LPS and upon activation recruits the NADPH-oxidase complex, Nox4 (Kaisho
& Akira, 2006; Park et al., 2004; Qureshi et al., 1999). Nox4 is then able to generate ROS
and promote proinflammatory cytokine expression (Ngkelo et al., 2012; Park et al., 2004).
To determine whether TLR4 was activated by K. kingae, we performed a
chemiluminescence bio-assay using a neutralizing rat IgG monoclonal antibody to human
TLR4 (anti-TLR4) to inhibit the biological activity of TLR4; an isotype control for rat
IgG1 was included as a negative control (Fig. 32, 33). LPS from Salmonella enterica
serotype enteritidis was included as a positive control for TLR4 activation and ROS
production by neutrophils (Fig. 32A). Preliminary data (n=1) suggest a slight reduction in
ROS production during neutrophil incubation with strain KK01csaA in the presence of the
anti-TLR4 antibody (Fig. 32C, 33B). No changes in ROS production were observed with
strains KK01, KK01pam, and KK01csaApam in either 1% HSA or 1% NHS in the presence
of the anti-TLR4 antibody (Fig. 32, 33). As previously demonstrated, the preliminary data
suggest a marked increase in ROS production when neutrophils are incubated with strain
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KK01csaApam (Fig. 32E, 33D). Currently, ongoing experiments are focused on improving
K. kingae LPS purification and structural analysis. Future studies will use purified K.
kingae LPS and polysaccharide capsule to determine changes in neutrophil TLR4
activation.

Figure 32: Detection of neutrophil TLR4 activation during K. kingae infection.
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Salmonella enterica serotype enteritidis LPS (A) and K. kingae rtx mutant strains,
KK01 (B), KK01csaA (C), KK01pam (D), and KK01csaApam (E) were incubated with
human neutrophils at an MOI of 10 in the presence of 1% HSA. Assays were
performed in the presence of 10µg/ml rat anti-TLR4 antibodies (triangles), 10µg/ml
rat IgG1 antibody control (squares), or media alone (circles). Chemiluminescence was
measured at 5-min intervals for 75 min for kinetic analysis. Gray plot points represent
neutrophil-only control (A-E). Data represents an n=1.

Figure 33: Detection of neutrophil TLR4 activation during K. kingae infection in the
presence of serum opsonins.
K. kingae rtx mutant strains, KK01 (A), KK01csaA (B), KK01pam (C), and
KK01csaApam (D) were incubated with human neutrophils at an MOI of 10 in the
presence of 1% NHS. Assays were performed in the presence of 10µg/ml rat antiTLR4 antibodies (triangles), 10µg/ml rat IgG1 antibody control (squares), or media
alone (circles). Chemiluminescence was measured at 5-min intervals for 75 min for
kinetic analysis. Gray plot points represent neutrophil-only control (A-E). Data
represents an n=1.
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5.6 Determine the mechanism by which exopolysaccharide inhibits
neutrophil phagocytosis
K. kingae bacterial association to human neutrophils was significantly increased in
the absence of the polysaccharide capsule (Ch. 3). Despite promoting neutrophil
association, the loss of capsule alone did not significantly increase neutrophil uptake and
phagocytosis (Ch. 3). Interestingly, elimination of both the capsule and exopolysaccharide
led to an increase in intracellular bacteria, suggesting that the exopolysaccharide inhibited
or delayed neutrophil uptake of associated bacteria (Ch. 3). We will perform live cell
fluorescence microscopy to investigate interactions between neutrophils and various
mutant strains of K. kingae KK01. To distinguish bacterial cells from neutrophils, we will
stain each population prior to infection with the appropriate fluorescent cellular dye. We
hypothesize that the exopolysaccharide may provide a physical barrier or blockage during
bacterial uptake. Alternatively, the exopolysaccharide may play a direct role in phagocytic
inhibition through interactions with neutrophil receptors. While the use of live cell
fluorescence microscopy may not provide direct answers as to whether the
exopolysaccharide is interacting with neutrophil receptors, visualization of neutrophilbacterial association will provide a better understanding of cellular dynamics during K.
kingae infection.

5.7 Effect of surface polysaccharides on cytokine expression and release
Beyond clearing pathogenic bacteria through intracellular and extracellular
mechanisms, neutrophils can release of a large subset of cytokines and chemokines upon
recruitment (Mayadas, Cullere, & Lowell, 2014; Mócsai, 2013). Various neutrophil
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receptors, including pathogen recognition receptors (PRR) as mentioned previously,
trigger cytokine and chemokine production (Scapini et al., 2000; Tecchio et al., 2014).
Given the differences in neutrophil activation upon infection with capsule-deficient
K. kingae, ELISA assays will be performed to determine the secretion of IL-1a, IL-1b, IL6, TNFa, and IFNg following incubation of neutrophils with K. kingae in the presence or
absence of serum opsonins. Additionally, we plan to determine proinflammatory and antiinflammatory cytokine transcript levels in infected neutrophils using qRT-PCR. Assays
will be performed using wild type and K. kingae mutants lacking the capsule,
exopolysaccharide, or both to establish how these surface polysaccharides influence
neutrophil cytokine expression and secretion. In Ch. 3, we demonstrated a lack of
neutrophil activation and neutrophil-mediated killing when the capsule was present. We
hypothesize that expression of the K. kingae polysaccharide capsule inhibits or reduces
cytokine release. As speculated in Ch. 5.5, we assume elimination of capsule leads to LPS
exposure and recognition by TLR4, thus triggering ROS production and perhaps changing
the cytokine profile.
While the loss of exopolysaccharide alone did not render K. kingae sensitive to
neutrophil-mediated killing, elimination of both surface polysaccharides promoted
phagocytosis of K. kingae, suggesting that the exopolysaccharide may inhibit or prevent
phagocytosis (Ch. 3). A reported galactan homopolysaccharide in Mycoplasma mycoides
subsp. mycoides similar to the K. kingae exopolysaccharide binds TLR2 and promotes the
production of anti-inflammatory cytokines (Totté et al., 2015). We hypothesize that the K.
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kingae exopolysaccharide may interact with neutrophil receptor(s) and prompt changes in
cytokine expression and secretion.

5.8 Determine regulatory elements for polysaccharide capsule
production
A mariner transposon mutagenesis strategy was implemented to determine essential
genes or loci for encapsulation of K. kingae strain KK01 (Starr, Porsch, Seed, & St. Geme
III, 2016). Around 10,000 transposon mutants were screened for a non-mucoid phenotype,
which is expected of non-encapsulated organisms (Starr, Porsch, Seed, & St. Geme III,
2016). Through screening and bioinformatic approaches, capsule export, assembly, and
biosynthesis genes were identified (ctrABCD operon, lipA, lipB, and csaA) (Starr, Porsch,
Seed, & St. Geme III, 2016). Despite successfully identifying genes necessary for
encapsulation, capsule regulatory components were absent from the transposon screen.
Unfortunately, the non-mucoid phenotype was not suitable for identification of regulatory
networks that alter the production and/or depth of the K. kingae capsule.
Recently, Dorman et al. employed a density-TraDISort strategy in K. pneumoniae
to determine genes that influence capsule production (Dorman et al., 2018). DensityTraDISort combines density gradient centrifugation using varying percentages of Percoll
with transposon insertion sequencing (Dorman et al., 2018). Our initial studies will
determine migration patterns of wild-type KK01 and various KK01 capsule-mutant strains.
We predict that optimization may be required to more accurately separate differentially
encapsulated K. kingae bacteria. We will perform thiobarbituric acid reactivity assays as
previously described to determine the amount of capsule present in each fraction and
validate expected separation patterns (Starr, Porsch, Seed, & St. Geme III, 2016; Straus,
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Lonon, Woods, & Garner, 1990; Warren, 1963). If K. kingae is amenable to density
centrifugation, genomic DNA from strain KK01pam will be used for the generation of a
transposon mutant library. Unlike K. pneumoniae, K. kingae strains express an
exopolysaccharide that may alter the migration pattern of non-encapsulated K. kingae. The
density-TraDISort strategy may be useful for identification of exopolysaccharide
regulatory elements. However, the exopolysaccharide is secreted and not membraneanchored like the polysaccharide capsule. Therefore, separation of bacteria based on levels
of exopolysaccharide release through centrifugation may not be plausible.
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